Page: 1
Protocol Number: CA209548
IND Number: 119590
Ex-US: Non-IND
EUDRACT Number: 2015-004722-34
Date: 16-Dec-2015
Revised Date: 02-Sep-2021
Clinical Protocol CA209548
A Randomized Phase 3 Single Blind Study of Temozolomide plus Radiation Therapy combined 
with Nivolumab or Placebo in New ly Diagnosed Adult Subjects with MGMT-Methylated (tumor 
O6-methylguanine DNA methyltransferase) Glioblastoma
(CheckMate 548 : CHECK point pathway and nivoluMA b clinical Trial Evaluation 548)
Protocol Amendment [ADDRESS_258925] Clinical Trial Physician -Medical Monitor
24-hr Emergency Telephone Number
Bristol
-Myers Squibb Company
Route 206 & Province Line Road
Lawrenceville, NJ [ZIP_CODE]
Avenue de Finlande 4
B-1420 Braine-lâ€™Alleud, Belgium
This document is the confidential and proprietary information of Bristol-Myers Squibb 
Company and its global affiliates (BMS). By [CONTACT_52212], you agree to keep it 
confidential and to use and disclose it solely for the purpose of assessing whether your 
organization will participate in and/or the performance of the proposed BMS-sponsored 
study. Any permitted disclosures will be made only on a confide ntial "need to know" basis 
within your organization or  to your independent ethics committee(s). Any other use, copying, 
disclosure or dissemination of this information is strictly prohibited unless expressly 
authorized in writing by [CONTACT_20444]. Any supplemental information (eg, amendments) that may 
be added to this document is also confidential and proprietary to BMS and must be kept in 
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_258926] Research Organization 
(CRO).
Â© 2020 Bristol-Myers Squibb Company
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 3DOCUMENT HISTORY
Document Date of Issue Summary of Change
Protocol 
Amendment 0702-Sep-2021Updated Appendix 1 Management Algorithms to include the version fr om 
Addendum No. 01 to the Nivolumab Investigator Brochure Version 19 (28-
Sep-2020) for studies using CTCAE version 4.0. Amended descriptio ns of 
DMC activities to clarify that DMC involvement does not continue after study unblinding. Updated COVID-19 vaccine risk/benefit and adm inistration 
guidance. Updated text regarding contraception for male subject s with female 
partners.
Protocol 
Amendment 0626-Feb-2021The Data Monitoring Committee (DMC) determined that there was no possibility for the study to have a positive overall survival ( OS) result, and 
recommended to unblind the sites and subjects, which was approv ed by [CONTACT_20444]. 
The study was officially unblinded on 22-Dec-2020. As a conseque nce, the 
timing of the primary OS analysis, originally planned for when [ADDRESS_258927]-enhanced magne tic resonance 
imaging (MRI) scans, clarification of the use of the term â€˜indeterminateâ€™ to 
describe the MGMT status of the tumor in some subjects, correct ions to 
hyperlink labels to Table [IP_ADDRESS]-1 in Table [IP_ADDRESS]-2, and cla rification that 
baseline MRI scan is the last scan prior to randomization that meets the diagnostic quality required in the imaging manual.
Administrative 
Letter 1018-Jul-2019 Removal of the interim analysis for Progression Free  Survival (PFS).
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 4Document Date of Issue Summary of Change
Revised 
Protocol 0508-Nov-2018Major Changes
â€¢Progression Free Survival is now a primary objective of the stu dy, changed 
from secondary.
â€¢Overall survival (OS) rate at 12 and 24 months and PFS based on  
investigator assessment by [CONTACT_215295].
â€¢Blinded Independent Central Review (BICR) of study images has been 
added to the study. 
â€¢The statistical section has been revised to support changes in the study objectives. The study will now include [ADDRESS_258928] recent version of the 
Investigator Brochure (version 15). The amendment also clarifies  several 
items as well as corrects minor errors.
â€¢Renal, Pulmonary, Hepatic, and Skin safety management algorithm s 
revised based on IBv.15
â€¢Time windows and technical descriptions around assessments and 
administration schedule have been added or expanded to allow for flexibility at the site level while not affecting the conduct or  the analysis 
of the data.
Revised 
Protocol 0122-Apr-[ADDRESS_258929] global amendment is to provide ad ditional 
clarification on several items in response to questions arising  from 
investigators and IRB/IEC/HAs: 
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 5Document Date of Issue Summary of Change
â€¢Add any â‰¥2 creatinine drug-related abnormality. 
â€¢Delete provision regarding delay in sub jects with baseline Grade [ADDRESS_258930] or total bilirubin toxicity to be allowed to continue dosin g to Grade â‰¥
3 toxicity, thus having all subjects delay for â‰¥Grade 2 drug-related 
toxicity.
â€¢Modify criteria to specify that s ubjects with Grade [ADDRESS_258931]/ALT, or total 
bilirubin elevations may resume dosing when lab values return to baseline and management with corticosteroids is complete.
â€¢Modify criteria to specify subjects must discontinue for any Grade 3 non-skin, drug-r elated adverse event lasti ng > 7 days or which recurs with some 
exceptions.
â€¢Modify criteria for drug-related liver function test abnormality  t o  
discontinue for AST or ALT > [ADDRESS_258932], Total bilirubin > [ADDRESS_258933] or ALT > [ADDRESS_258934] and total bilirubin > [ADDRESS_258935].
â€¢Add a definition for single blind.  
Additional modifications are as described below:
â€¢Revise resection cutoffs 
â€¢Clarify time wi ndows and techn ical descriptions around the infusion, 
examinations, and administration schedule
â€¢Remove exclusion criteria 2d for subjects with interstitial lung disease 
â€¢Add exclusion criteria 2k to exclude subjects with prior hyperse nsitivity to 
dacarbazine (DTIC)
â€¢Add a Radiotherapy Guideline Appendix
â€¢Move Highly Effective Methods of Contraception to an Appendix
â€¢Incorporate other minor changes to correct and/or clarify protocol 
requirements
Original 
Protocol16-Dec-2015 Not applicable
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
OVERALL RATIONALE FOR PROTOCOL AMENDMENT 07:
It was determined following finalization of Protocol Amendment 06 that the Protocol Appendix 1 
Management Algorithms were not the  current version as included in the Nivolumab Investigator 
Brochure. Appendix 1 has been updated to include the MANAGEMENT  ALGORITHMS FOR 
STUDIES UNDER CTCAE VERSION 4.0 from Addendum No. 01 to the Nivo lumab Investigator 
Brochure Version 19 (28-Sep-2020).
Descriptions of Data Monitori ng Committee (DMC) acti vities are amended to clarify that DMC 
involvement does not continue after study unblinding. Clarifica tion is added regarding COVID-19 
vaccine benefit risk and administration. The protocol instructi ons regarding contraception in male 
study participants who are sexually active with women of childb earing potential are updated to 
align with the temozolomide (TMZ) summary of product characterist ics (SmPC) or other local 
regulation. Other minor changes are made for consistency throug hout the protocol.
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 07
Section Number & Title Description of Change Brief Rationale
Protocol Summary Study 
Design;Section 3.1 : Study Design and 
Duration;Section 7 : Data Monitoring 
Committee and Other External CommitteesClarified that subjects may remain on nivolumab and TMZ treatment following study unblinding.Clarified that DMC activities cease following study unblinding.Subjects may remain on study treatment post-unblinding and will be followed only through the safety follow-up phase. Limited reporting will be completed and subject safety will be monitored by [CONTACT_456]. 
Section 3.1.4: Overall Study Duration;
Section 8.5 : Interim AnalysesText regarding a progression free survival 
(PFS) interim analysis (IA) was removed.The PFS IA was previously 
removed from the protocol, but 
references to it were inadvertently 
left in Section 3.1.4 and Section 8.
Section 3.3.1: Inclusion Criteria Inclusion Criterion 3e was revised.The requirement is updated to align with the TMZ summary of 
product characteristics or other local regulatory document.
Section 3.4: Concomitant Treatments;Section 3.4.1: Prohibited and/or Restricted TreatmentsAdded text regarding COVID-19 vaccines.Clarified that non-live Covid-19 vaccines are allowed and are to be handled in the same manner as other non-live vaccines.
Section [IP_ADDRESS]: Management Algorithms for Immuno-Oncology Agents;
Appendix 1: Management 
AlgorithmsAdded myocarditis to the list of adverse event groups for which a management algorithm is included in Appendix 1.
Management algorithms updated to 
current version for studies using CTCAE Version 4.0.Updated to align with Addendum No. 01 to the nivolumab Investigator Brochure Version 19 
(28-Sep-2020) and m ore-recent 
version of the management 
algorithms.
Section 5.1: Flow Chart/Time and Events Schedule;Table 5.1-2  On-treatment Assessments
adverse event assessment note updated to include discontinuation from study.Aligned with simplified procedures following study unblinding; subsequent response, survival,  
are no longer needed.
Protocol Amendment No.: 07
Date: 02-Sep-2021 6
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 07
Section Number & Title Description of Change Brief Rationale
Section 6.4: PregnancyInstruction that a pregnancy occurring in 
the female partner of a male subject within [ADDRESS_258936] characteristics or other local regulatory document.
Protocol Amendment No.: 07
Date: 02-Sep-2021 7
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
PROTOCOL SUMMARY
Clinical Protocol CA209548
Protocol Title: A Randomized Phase 3 Single Blind Study of Temozolomide plus Radiation Therapy combined with 
Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGM T-Methylated (tumor O6-methylguanine DNA 
methyltransferase) Glioblastoma
Investigational Product(s), Dose and Mode of Administration, Duration of Treatment with Investigational 
Product(s): Nivolumab (BMS-936558) 240 mg IV or p lacebo as a 30 minute infusion every 2 weeks for 8 doses
followed by [CONTACT_20382] 480 mg as a 30 minute infusion every 4 wee ks beginning after 8 doses until progression, 
unacceptable toxicity (or other reasons), and temozolomide 75 mg/m2orally d ailyduring radiation therapy followed 
by 4 week break then 6 (28-day) cycles temozolomide on Days 1-5  at 150 mg/m2in Cycle 1 increasing to 200 mg/m2
as tolerated up to 6 cycles. 
Study Phase: 3
Research Hypothesis: Addition of nivolumab to standard radiotherapy (RT) plus temozolomide (TMZ) will increase 
PFS in subjects wit h newly-diagnosed GBM of MGMT- methylated or ind eterminate subtypes and will increase OS 
in subjects with newly-d iagnosed GBM of MGMT- methylated or ind eterminate subtypes without bas eline 
corticosteroids and regardless of baseline corticosteroids.
Objectives:
Primary Objective:
The two primary objectives are: 
â€¢To compare PFS of subjects with newly-diagnosed MGMT methylated  or indeterminate GBM subtypes 
treated with RT plus TMZ combined with nivolumab or placebo. PFS  will be determined by [CONTACT_215296].
â€¢To compare OS of subjects with newly-diagnosed MGMT methylated or indeterminate GBM subtypes 
without baseline corticosteroids and regardless of baseline cor ticosteroids (ie, all-comers) treated with RT 
plus TMZ combined with nivolumab or placebo.
Secondary Objective:
â€¢To compare OS of subjects with newly-diagnosed MGMT methylated or indeterminate GBM subtypes 
without baseline corticosteroids and regardless of baseline cor ticosteroids (ie, all comers) treated with RT 
plus TMZ combined with nivolumab or placebo at 12 and 24 months .
â€¢To compare PFS based on inves tigator assessment by [CONTACT_215297] a of subjects with newly-diagnosed 
MGMT methylated or indeterminate GBM subtypes treated with RT plus TMZ combined with nivolumab or 
placebo. 
Protocol Amendment No.: 07
Date: 02-Sep-2021 8
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Study Design:
Th
is study w ill enroll subjects with newly-diagnosed GBM, following surgical  resection of the tumor. Tumor tissue 
will be evaluated for MGMT methylation by a central laboratory assay through the CA209498 study. After enrolling 
in the CA209498 study, the subjects may e nroll in the CA209548 study and begin the screening process whi le they 
wait for the MGMT results. The screening number assigned in the  CA209498 IVRS will be the same subject number 
entered by [CONTACT_215298]209548 IVR S. Those with a MGMT status of methylated or 
indeterminate may be eligible to randomize in the CA209548 stud y.
In order to randomize 693 eligible subjects, a total of approximately 780 subjects are expected to be enrolled. After 
signing consent, eligibility for randomization will be document ed. When ready to begin study treatment, subjects will 
be randomized in a 1:1 ratio to the RT/TMZ/nivolumab or the RT/ TMZ/placebo arm, stratified by [CONTACT_215299]. complete 
resection. All subjects who enter the treatment phase, ie, all randomized subjects, will be  followed for safety and 
tolerability, tumor progression and survival. 
A contrast-enhanced MRI should be performed approximately 4 wee ks (Â±7 days) after completing radiation therapy, 
then every 8 weeks ( Â±7 days) up to [ADDRESS_258937] ra ndomization, then every 12 weeks  until progression regardless 
of treatment schedule or dose delay. Tumor progression will be a ssessed using Radiologic Assessment in Neuro-
Oncology criteria (RANO).  
On 09-Dec-2020 the Data Monitoring Committee (DMC) conducted a pre -planned routine safety review of all 
available safety data, and initially recommended that the study  continue unchanged. Subsequently, the DMC noted 
that it is not possible for the study to demonstrate an OS bene fit for the investigational treatment arm, and after further 
discussion with the DMC, the decision was made to unblind all st udy subjects, and inform all investigators, ethics 
committees, and health authorities as required. Following study  unblinding, subjects may continue nivolumab and/or 
TMZ (if applicable) treatment, following protocol procedures. A fter cessation of nivolumab and/or TMZ treatment 
for any reason, all randomized sub jects will enter a short follow-up phase for reporting of treat ment-related adverse 
events. Subjects in whom disease progression had not been detect ed at the time st udy tr eatment is stopped will no 
longer be followed for progression. All subjects will no longer be followed for survival.
A DMC will meet regularly during the study until study unblinding to ensure that subject safety is carefully monitored.
Protocol Amendment No.: 07
Date: 02-Sep-2021 9
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Study Schematic:
Following unblinding, subjects may continue on nivolumab and/or temozolomide (if applicable) treatment, 
following protocol procedures. 
Study Population : Subjects must meet all eligibility criteria specified in Sections 3.3.1 and 3.3.2 of the protocol, 
including the following:
Key Inclusion criteria:
â€¢Males and females age â‰¥18 years old
â€¢Newly diagnosed histologically confirmed supratentorial gliobla stoma (Grade 4 malignant glioma by [CONTACT_215300])
a) No treatment for GBM other than surgery
b) Post-operative baseline MRI following consensus recommendatio ns must be obtained prior to 
randomization. It is strongly recommended that this scan be obt ained <72 hours or >[ADDRESS_258938] 
â€¢Substantial recovery from surgical resection
a) No major ongoing safety issues (eg infection requiring IV antibiotics) following surgery
b) For subjects on corticosteroids at the time of Screening: able to taper steroids (preferably discontinued). 
Dose at randomization must be â‰¤20 mg prednisone daily or â‰¤3 mg dexamethasone daily (or equivalent)
â€¢As of Amendment 11, this criterion regarding screen fails from CA209498 is not applicable. 
â€¢Centrally confirmed (ie, third-party vendor) tumor MGMT-methylate d or indeterminate from the CA209498 
study
â€¢Karnofsky performance status of â‰¥70
â€¢Clinically appropriate for concomitant temozolomide plus RT, based on investigator judgement
Protocol Amendment No.: 07
Date: 02-Sep-2021 10
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Key Exclusion Criteria:
â€¢Prior treatment for GBM (other than surgical resection)
â€¢Recurrent GBM
â€¢MGMT-un methylated GBM at central laboratory or tumor not availa ble
â€¢Biopsy-only of GBM at surgery, defined as < 20% resection of enha ncing tumor
â€¢Concomitant use of Gliadel Â®wafer
â€¢CNS hemorrhage of Grade > [ADDRESS_258939] resolved
â€¢Any known metastatic extracranial or leptomeningeal disease
â€¢Secondary GBM (ie, progression from prior low-grade or anaplastic astrocytoma)
Study Drug: includes both Investigational [Medicinal] Products (IP/IMP) and Non-investigational [Medicinal] 
Products (Non-IP/Non-IMP) as listed:
Study Drug for CA209548
Medication Potency IP/Non-IP 
Nivolumab Solution for Injection 100 mg (10 mg/mL) IP
Placebo N/A IP
Temozolomide 20 mg, 100 mg, 140 mg IP
Subjects should begin study tr eatment within 3 days of randomization and chemoradiation withi n 7 days, but RT 
should begin within 42 days after definitive resection; may be delayed if clinically required. Subjects will continue on 
study treatment until progression, unacceptable toxicity, withd rawal of consent, or the study ends, whichever comes 
first. 
Study Assessments:
Safety Evaluation: Adverse events will be assessed continuously during the study and for [ADDRESS_258940] recovered to baseline or are deemed irreversible by [CONTACT_093]. 
Efficacy Assessments: Post-operative baseline MRI following consensus recommendations must be obtained prior to 
randomization. It is strongly recommended that this scan be obt ained <72 hours or >[ADDRESS_258941]. Tumor imaging assessments following recent co nsensus recommendations will occur 4 weeks 
(Â±7 days) after completion of radiotherapy (baseline MRI) then eve ry  8  w e e k s  ( Â±7 days) up to [ADDRESS_258942] discontinued all study treat ment. Per RANO, assessment of disease progression 
during study requires that MRI scan be performed >12 weeks after RT; it is therefore recommended that second on-
treatment scan be per formed at least [ADDRESS_258943]-treatment Follow-up visits 1 
and 2 (~[ADDRESS_258944] dose); following study unblindi ng, Follow- up visits 1 and 2 are only required for 
subjects discontinuing nivolumab and/or temozolomide. Survival status will be assessed every 3 months after follow-
up visits are completed and may be  completed via telephone or at in person visits; following study unblinding, survival 
status will not be assessed. Images will be submitted to a centr al imaging vendor for blinded independent central 
Protocol Amendment No.: 07
Date: 02-Sep-2021 11
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
review (BICR) at any time during the study until study unblinding. Prior to scanning first participant, sites should be 
qualified and understand the image acquisition guidelines and s ubmission process as outlined in the CA209-548 
Imaging Manual provided by [CONTACT_11343].
Statistical Considerations:
Sample Size: Approximately 693 subjects will be randomized in a 1:1 ratio, s tratified by [CONTACT_215301]. 
Of these 693 subjects, 485 subjects are assumed to be considere d as no baseline corticosteroids. Accrual is estimated 
to take approximately 25 months based on an observed monthly accr ual in CA209548 of approximately 28 subjects 
per month; in the no baseline corticosteroids population, a pie cewise accrual of 1, 4, 5, 8, 13, 16, 19, and then 
[ADDRESS_258945] 337 OS even ts in no baseline corticosteroid population are needed 
to achieve 88% power using a 2-sided Type 1 error of 4%. This n umber of events is projected to occur after an 
additional 44 months of follow-up (ie, at 69 months). 
One interim analysis will be conducted on OS in the randomized po pulation with no baseline corticosteroid.  It will 
occur with approximately 70% or 236 OS events is reached. The stoppi[INVESTIGATOR_215274], using Lan DeMets alpha spending function with Oâ€™Brien-Fleming boundaries. If the planned interim analyses occur exactly at the planned number of events, the 
projected alpha level will be 0.011 and 0.037. The interim analys is will also be conducted in OS in the overall 
randomized population. The interim analysis will be conducted at the same time as the interim for the no baseline 
corticosteroids population in a hierarchy with stoppi[INVESTIGATOR_215275]-DeMet s alpha spending function with Oâ€™Brien-Fleming 
boundaries. 
The PFS comparisons will be  based on first [ADDRESS_258946] 404 PFS events are needed 
to achieve 90% power using a 2-sided Type 1 error of 1%. Accrua l is estimated to take approximately 23 months and 
this number of events is projected to occur after an additional  12 months of follow-up (ie, at 35 months).
Endpoints:
The two primary endpoints of the trial will be OS in the randomiz ed population with no corticosteroids at baseline as 
well as in the overall rando mized population, and PFS determined by [CONTACT_215302].
Secondary endpoints: OS rate at 12 months and 24 months estimate d from OS Kaplan-Meier curve. PFS determined 
by [CONTACT_215303].
Analyses:
Primary EndpointsOS is defined as time from the date of randomization to the dat e of death. Subjects who have not died by [CONTACT_215304]. OS will be  assessed in the randomized population with no 
corticosteroids at baseline population and in the overall randomized population.
The distribution of OS in the sub-population of subjects with n o baseline corticosteroids and in all randomized subjects 
will be compared in arms RT + TMZ + nivolumab and RT + TMZ at i nterim and final analyses via two-sided, log-rank 
tests, stratified by [CONTACT_215305]. The boundaries for declaring superiority at the 
interim and final analyses w ill be based on the actual number of OS events at the time of the analysis using Lan DeMets 
alpha spending function with Oâ€™Brien-Fleming boundaries. For example, if the interim and fi nal analyses occur exactly 
at the planned number of events, superiority of an arm will be declared if P â‰¤ 0.011 at the interim analysis or P â‰¤0.[ADDRESS_258947] limit method wi ll be used to estimate the survival curve in each arm 
including medians and its 95% CI, OS rates at various time poin ts. The HR and the corresponding two sided 
(1-adjusted Î±) % CIs will be estimated in a Cox proportional hazards model with treatment arm as a single covariate 
stratified by [CONTACT_215306] (complete or partial surgical resection at baseline).
PFS is defined as the time from randomization to the date of the first documented tumor progression or death by [CONTACT_215307]. Subjects who did not have disease progression or die will be censored at the date of the last tumor assessment. 
Subjects who did not have any on study tumor assessment and did  not die will be censored at the last tumor assessment. 
Subjects who started any subsequent anti-cancer therapy without  a prior reported progression will be censored at the 
last tumor assessment prior to initiation of the anti-cancer th erapy. Subjects w
 ho had surgical resection after start of 
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_258948] tumor assessment d ate prior to initiation of surgical resection. PFS will be 
determined by [CONTACT_215302]. 
The comparison of PFS will be based on a two-sided log-rank tes t stratified by [CONTACT_215306] 
(complete surgical or partial resection at bas eline). PFS will be compared in the first 558 subjects out of the (total) 
[ADDRESS_258949] limit method wil l be used to estimate the survival curve in each arm 
including medians and its 95%  CI, PFS rates at various time points. The HR a nd the corres ponding two sided 99% 
CIs will be estimated in a Cox proportional hazards model with treatment arm as a single covariate stratified by 
[CONTACT_215306] (complete or partial surgical resection at baseline).PFS (based on BICR) will be an alyzed in overall randomized subj ects and all randomized subjects without baseline 
corticosteroids.The CA209548 DMC convened on 09-Dec-[ADDRESS_258950] a positive OS result at the final analys is 
based on either all randomized sub jects or on subjects wit hout baseline corticosteroids. This is based on the DMCâ€™s 
review of the OS results to date, with over 80% of the final required number of events reached and related statistical 
considerations including conditional power of < 1% for a statistically significant final result.
While the group receiving nivolumab has a higher incidence of toxicities, the DMC members believed the increased 
toxicity was expected and did not warrant stoppi[INVESTIGATOR_215276], and recommended to unblind the sites 
and subjects, which was approved by [CONTACT_1034]. The study was officially unblinded to investigators on 22-Dec -2020.
As a consequence, the timing of th e primary OS analysis, origina lly planned when 337 and 494 events were to be 
reached respectively for the population without corticosteroids  at baseline and the overall population, has been 
updated. To prevent any bias due to unblinding of subjects, the primary OS analysis will be conducted using the cut-
off date (or last patient last visit [LPLV]) of 22-Dec-2020, wh ich is when the study was unblinded.
Secondary Endpoint
OS rates at [ADDRESS_258951] 558 subjects, all randomized subjects and all 
randomized subjects who did not receive corticosteroids at base line.
All secondary endpoints will be analyzed at the same time as th e OS and PFS primary analyses using the analysis 
methods already defined in the SAP.
Protocol Amendment No.: 07
Date: 02-Sep-2021 13
Approved 8.0 v

TABLE OF CONTENTS 
TITLE PAGE ................................................................................................................ 
DOCUMENT HISTORY .............................................. ................................................ 
OVERALL RATIONALE FOR PROTOCOL AMENDMENT 07: ............................ 
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 07 ................ 
PROTOCOL SUMMARY ............................................................................................ 
TABLE OF CONTENTS ..............................................................................................  
1 INTRODUCTION  ............................ .........................  
1.2 Research Hypothesis ....................................... ..................................................  
1.3 Objective(s) .............................................. .........................................................  
1.3.[ADDRESS_258952]/Independent Ethics Committee .............................  
2.3 Informed Consent........................................... ...................................................  
3 INVESTIGATIONAL PLAN ....................................................................................  
3.1 Study Design and Duration ...............................................................................  
3.1.1 Screening Phase .......................................................................................  
3.1.2 Treatment Phase ......................................................................................  
[IP_ADDRESS] Randomization and Initiation of Treatment ....................................  
[IP_ADDRESS] Radiotherapy ...................................................................................  
3.1.[ADDRESS_258953] Study Access to Therapy .............................. .............................................  



















Clinical Protocol
BMS-936558CA209548
nivolumab
Protocol Amendment No.: 07Date: 02-Sep-2021 14
Approved 8.0 v

3.3 Study Population .......................................... .....................................................  
3.3.1 Inclusion Criteria .....................................................................................  
3.3.2 Exclusion Criteria ....................................................................................  
3.3.3 Women of Childbearing Potential ...........................................................  
3.4 Concomitant Treatments .................................... ...............................................  
3.4.1 Prohibited and/or Restricted Treatments.................................................  
3.4.2 Other Restrictions and Precautions .........................................................  
[IP_ADDRESS] Imaging Restriction and Precautions .............................................  
3.4.[ADDRESS_258954] ............................... ..............................................  
4.3 Storage of Study Drug ......................................................................................  
4.3.1 Nivolumab (BMS-936558) .......................................................................  
4.3.[ADDRESS_258955] ............. ..................................  
4.5.1 Nivolumab/Placebo Dosing .....................................................................  
[IP_ADDRESS] Nivolumab/Placebo Dose and Schedule .........................................  
[IP_ADDRESS] Dose Modifications for Nivolumab/Placebo ...................................  
[IP_ADDRESS] Dose Delay Criteria for Nivolumab/Placebo .................................  
[IP_ADDRESS] Criteria to Resume Dosing for Nivolumab/Placebo .......................  
[IP_ADDRESS] Treatment Discontinuation Criteria for Nivolumab/Placebo .........  
[IP_ADDRESS] Continuing Nivolumab/Placebo with Suspected Progression ........  
[IP_ADDRESS] Management Algorithms for Immuno-Oncology Agents ................  
[IP_ADDRESS] Treatment of Nivolumab/Placebo-Related Infusion Reactions .......  
4.5.2 Temozolomide Dosing ..............................................................................  
[IP_ADDRESS] Temozolomide Dose and Schedule ..................................................  
[IP_ADDRESS] Criteria to Start Temozolomide Maintenance Cycles .....................  
[IP_ADDRESS] Dose Modifications or Discontinuation for Temozolomide ............  
[IP_ADDRESS] Supportive Care during Temozolomide ..........................................  
4.6 Blinding/Unblinding .........................................................................................  
4.[ADDRESS_258956] .......... ...................................  
4.9 Retained Samples for Bioavailability/Bioequivalence ....... ..............................  
5 STUDY ASSESSMENTS AND PROCEDURES ............................ .........................  
5.1 Flow Chart/Time and Events Schedule ....................... ......................................  
5.1.1 Retesting During Screening or Lead-in Period .......................................  
5.2 Study Materials .................................................................................................  
5.3 Safety Assessments ........................................ ...................................................  
5.4 Efficacy Assessments ........................................................................................  
5.4.1 Suspected Progression .............................................................................  




































Clinical Protocol
BMS-936558CA209548
nivolumab
Protocol Amendment No.: 07Date: 02-Sep-2021 15
Approved 8.0 v

5.4.2 Assessment of Response ...........................................................................  
5.6.1 Tumor Samples.........................................................................................  
[IP_ADDRESS] Tumor Sample Collection Details ...................................................  
[IP_ADDRESS] MGMT Status ..................................................................................  
5.[ADDRESS_258957] Result Abnormalities ..............................................................  
6.4 Pregnancy ................................................. .........................................................  
6.5 Overdose .................................................. .........................................................  
6.6 Potential Drug Induced Liver Injury (DILI) .....................................................  
6.7 Other Safety Considerations ............................... ..............................................  
7 DATA MONITORING COMMITTEE AND OTHER EXTERNAL COMMITTEES
.................................................................................................................................  
8 STATISTICAL CONSIDERATIONS................................... ....................................  
8.1 Sample Size Determination ................................. ..............................................  
8.2 Populations for Analyses .................................. ................................................  
8.3 Endpoints ..........................................................................................................  
8.3.1 Primary Endpoint(s) ................................................................................  
8.3.2 Secondary Endpoint(s) .............................................................................  
 
8.4 Analyses ............................................................................................................  





















Clinical Protocol
BMS-936558CA209548
nivolumab
Protocol Amendment No.: 07Date: 02-Sep-2021 16
Approved 8.0 v

8.4.1 Demographics and Baseline Characteristics ..........................................  
8.4.2 Efficacy Analyses .....................................................................................  
[IP_ADDRESS] Analyses of Primary Endpoint ........................................................  
[IP_ADDRESS] Analyses of Secondary Endpoints ...................................................  
8.4.3 Safety Analyses.........................................................................................  
8.5 Interim Analyses .......................................... .....................................................  
8.6 End of Study Analyses at Study Closure ..........................................................  
9 STUDY MANAGEMENT ........................................................................................  
9.1 Compliance ................................................ .......................................................  
9.1.1 Compliance with the Protocol and Protocol Revisions ...........................  
9.1.2 Monitoring ...............................................................................................  
[IP_ADDRESS] Source Documentation ....................................................................  
9.[ADDRESS_258958] OF ABBREVIATIONS ..................................................................................  
APPENDIX 1 MANAGEMENT ALGORITHMS FOR STUDIES UNDER CTCAE 
VERSION 4.0 .........................................................................................................  
APPENDIX 2 RADIATION THERAPY GUIDELINES ....................... .....................  
APPENDIX 3 KARNOFSKY PERFORMANCE SCALES ....................... .................  
APPENDIX 4 HIGHLY EFFECTIVE METHODS OF CONTRACEPTION .............  
APPENDIX 5 PROTOCOL AMENDMENT SUMMARY OF CHANGE HISTORY
.................................................................................................................................  




















Clinical Protocol
BMS-936558CA209548
nivolumab
Protocol Amendment No.: 07Date: 02-Sep-2021 17
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
1 INTRODUCTION 
Protocol Amendment No.: 07
Date: 02-Sep-2021 18
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 19
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 20
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 21
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 22
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 23
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 24
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 25
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_258959] radiotherapy (RT) plus temozol omide (TMZ) will increase PFS 
in subjects with newly-diagnosed GBM of MGMT-methylated or indeterminate subtypes and will 
increase OS in subjects with newly-diagnosed GBM of MGMT-methyl ated or indeterminate 
subtypes without baseline corticosteroids and regardless of base line corticosteroids.
1.3 Objective(s)
1.3.1 Primary Objectivesâ€¢To compare PFS of subjects with  newly-diagnosed MGMT-methylated  or indeterminate 
GBM subtypes treated with RT plus TMZ combined with nivolumab or placebo. PFS will be 
determined by [CONTACT_19375] (BICR) based on  RANO criteria.
â€¢To compare OS of subjects with newly-diagnosed MGMT-methylated or indeterminate GBM 
subtypes without baseline corticosteroids and regardless of bas eline corticosteroids (ie, all 
comers) treated with RT plus T MZ combined wit h nivolumab or pla cebo.
1.3.2 Secondary Objectives
â€¢To compare OS of subjects with newly-diagnosed MGMT-methylated or indeterminate GBM 
subtypes without baseline corticosteroids and regardless of baseline corticosteroids (ie, all 
comers) treated with RT plus TMZ combined wit h nivoluma b or placebo at 12 and 24 months.
â€¢To compare PFS based on investigator assessment by [CONTACT_215308]-diagnosed MGMT methylated or indeterminate GBM subtypes t reated with RT plus 
TMZ combined with nivoluma b or placebo.
Protocol Amendment No.: 07
Date: 02-Sep-2021 27
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 28
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 29
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 30
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
2 ETHICAL CONSIDERATIONS
2.1
Good Clinical Practice
This study will be conducted in accordance with Good Clinical P ractice (GCP), as defined by [CONTACT_20417] (ICH) and in accordan ce with the ethical principles 
Protocol Amendment No.: 07
Date: 02-Sep-2021 31
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
underlying European Union Directive 2001/20/EC and the [LOCATION_002] Code of Federal 
Regulations, Title 21, Part 50 (21CFR50) and applicable local requirements.
The study will be conducted in compliance with the protocol. Th e protocol and any amendments 
and the subject informed consent will r eceive Institutional Review Board/Independent Ethics 
Committee (IRB/IEC), if applicable, also by [CONTACT_215309]/favorable opi[INVESTIGATOR_215277].
All potential serious breaches must be reported to Sponsor or designee immediately. A serious 
breach is a breach of the conditions and principles of GCP in co nnection with the study or the 
protocol, which is lik ely to affect, to a significant degree, t he safety or physical or mental integrity 
of the subjects of the study or the scientific value of the stu dy.
Personnel involved in conducting this study will be qualified b y education, training, and 
experience to perform their respective tasks.
This study will not use the services of study personnel where s anctions have been invoked or where 
there has been scientific misconduct or fraud (eg, loss of medi cal licensure, debarment). 
2.[ADDRESS_258960]/Independent Ethics Committee 
Before study initiation, the investigator must have written and  dated approval/favorable opi[INVESTIGATOR_20291]/IEC and Regulatory Authority(ies), if required by [CONTACT_215310], 
consent form, subject recruitment m aterials (eg, advertis ements), and any other written 
information to be provided to subjects. The investigator or BMS  should also provide the IRB/IEC 
or local health authority with a copy of the Investigator Broch ure or product labeling information 
to be provided to subjects and any updates. 
The investigator, Sponsor or desi gnee shoul d provide the IRB/IEC or local health authority with 
reports, updates and other information (eg, expedited safety re ports, amendments, and 
administrative letters) according to regulatory requirements or  institution procedures.
2.[ADDRESS_258961] ensure that subjects are clearly and fully i nformed about the purpose, potential 
risks, and other crit ical issues regardi ng clinical studies in which they volunteer to participate. 
In situations where consent cannot be given to subjects, their legally acceptable representatives 
(as per country guidelines) are clearly and fully informed a bout the purpose, po tential risks, and 
other critical issues regarding clinical studies in which the s ubject volunteers to participate. 
Sponsor or designee will provide the investigator with an appro priate (ie, Global or Local) sample 
informed consent form which will include all elements required by [CONTACT_12212], GCP and applicable 
regulatory requirements. The sample informed consent form will adhere to the ethical principles 
that have their origin in the Declaration of Helsinki.
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_258962]:
â€¢Provide a copy of the consent  form and written information abou t the study in the language in 
which the subject is most proficient prior to clinical study pa rticipation. The language must be 
non-technical and easily understood. 
â€¢Allow time necessary for subject or subject's legally acceptabl e representative to inquire about 
the details of the study.
â€¢Obtain an informed consent signed and personally dated by [CONTACT_29159]'s legally 
acceptable representative and by [CONTACT_35884] i nformed consent discussion. 
â€¢Obtain the IRB/IECâ€™s written approval/favorable opi[INVESTIGATOR_82705], prior  to the beginning of the study, 
and after any revisions are completed for new information.
â€¢If informed consent is initially given by a subjectâ€™s legally a cceptable representative or legal 
guardian, and the subject subsequently becomes capable of makin g and communicating his or 
her informed consent during the study, consent must additionall y be obtained from the subject.
â€¢Revise the informed consent whenever important new information becomes available that is 
relevant to the subject's consent. The investigator, or a perso n designated by [CONTACT_093], 
should fully  inform the subject or the subject's legally accept able representative or legal 
guardian, of all pertinent aspects of the study and of any new information relevant to the 
subject's willingness to continue participation in the study. This communication should be 
documented. 
The confidentiality of records that could identify subjects mus t be protected, respecting the privacy 
and confidentiality rules applicable to regulatory requirements , the subjects' signed ICF and, in the 
US, the subjectsâ€™ signed HIPAA Authorization.
The consent form must also include a statement that BMS and reg ulatory authorities have direct 
access to subject records. 
Subjects unable to give their written consent (eg, stroke or subjects with or severe dementia), may 
only be enrolled in the study with the consent of a legally-acc eptable representative. The subject 
must also be informed about the nature of the study to the exte nt compatible with his or her 
understanding, and should this subject become capable, he or she should personally sign and date 
the consent form as soon as possible. The exp licit wish of a sub ject who is unable t o give his or 
her written consent, but is capable of forming an opi[INVESTIGATOR_138515] a ssessing information, to refuse 
participation in, or to be withdrawn from, the clinical study at any time s hould be considered by 
[CONTACT_093].
The rights, safety, and well-being of the study subjects are th e most important considerations and 
should prevail over interests of science and society.
3 INVESTIGATIONAL PLAN
3.1 Study Design and Duration
This study will e nroll subjects with newly-diagnosed GBM, following surgical res ection of the 
tumor. Tumor tissue will be evaluated for MGMT methylation by a central la boratory assay 
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_258963] into the CA209548 IVRS. Those wit h a MGMT status of methylated 
or indeterminate may be eligible to randomize in the CA209548 s tudy. In order to rando mize 
693 eligible subjects, a total of approximately 780 sub jects w ill be evaluated. For details, see 
Section 3.1.1 . 
Subjects with a central laboratory result of MGMT-methylated or  indeterminate may continue in 
the screening phase, in which eligibility for randomization will be documented and baseline 
demographic and disease information submitted; for details, see  Section 3.1.[ADDRESS_258964] udy treatment, subj ects will proceed to t he treatment phase of the study; 
for details, see Section 3.1.[ADDRESS_258965]-enhanced MRI should be performed 4 weeks ( Â±7 days) after completing 
radiation therapy, then subsequent scans should be every 8 weeks  (Â±7 days) up to 24 months, then 
every 12 weeks until progression regardless of treatment schedu le or dose delays. Tumor 
progression will be assessed using RANO described in Section 5.4.2 .  
 
 For the purposes of this protocol, each cycle  duration is 2 weeks until 8 doses of 
240 mg of nivolumab/placebo are com plete. The remaining subsequ ent cycles (480 mg or placebo 
infusio n, starting Week 17 in the absence of delays) are 4 weeks in dur ation. Cycle 9 should start 
2 weeks after Cycle 8 begins. 
After cessation of all study treatment for a ny reason, all randomized subjects will enter a follow-up 
phase. In the short-term, visits are defined for reporting of t reatment-related adverse events. 
Following study unblinding, subjects who discontinue all tr eatment w ill not be followed for 
progression per RANO criteria, or for survival. For details on th e follow-up phase, see Section  
3.1.3 . 
Baseline and all subsequent scans will be submitted to blinded independent central review (BICR) 
for review, once the subject is randomized and until study unbli nding on 22-Dec-2020. 
A Data Monitoring Committee (DMC) will meet regularly during the study until study unblinding 
to ensure that subject safety is carefully monitored, see Section 7 .
The study design schematic is presented in Figure 3.1-1 .
Protocol Amendment No.: 07
Date: 02-Sep-2021 34
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Figure 3.1-1: Study Design Schematic
Following unblinding, subjects may continue on nivolumab and/or t emozolomide (if 
applicable) treatment, following all protocol procedures.
3.1.1 Screening Phase
Subjects will provide consent for enrollment and tumor submissi on in the peri-operative period in 
the CA209498 study so that MGMT status can be determined. Consent for enrollment in the
CA209548 study will o ccur while waiting for the MGMT results to  be obtained and randomization 
and study treatment w ill occur once MGMT s tatus of methylated or ind eterminate is known and 
eligibility is established ( Figure 3.1.1- 1).  
Protocol Amendment No.: 07
Date: 02-Sep-2021 35
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Figure 3.1.1-1: Screening and Randomization
A centralized tumor tissue assay for MGMT is required as part o f the CA209498 MGMT testing. 
Subjects will consent to the MGMT testing and the CA209548 stud y simultaneously. Following 
informed consent for both studi es, subjects will be enrolled vi a a call to an IVRS system f or the 
CA209498 MGMT testing, in order to obtain a s ubject number. Imm ediately after the subject 
number is obtained from the CA [ADDRESS_258966] be entered into 
the eCRF. 
When possible, subjects  should not be on cor ticosteroids at Scr eening. It is expected that 
corticosteroid therapy will be tapered to the maximum extent po ssible during this phase. Subjects 
who cannot tolerate tapering of steroids to < 20 mg prednisone o r < 3 mg dexamethasone per day 
(or equivalent) are not eligible for randomization.RT should begin within 42 days of surgical resection but may be dela yed if clinically required. 
Typi[INVESTIGATOR_897], the time from screening procedure to treatment should  not exceed 28 days, but may be 
longer if clinically indicated. If repeat resection to improve tumor control is performed for 
newly-diagnosed GBM pri or to any other therapy (eg, upon referral to research site), the 42-day 
interval should restart at the time of this second s urgery and a new post-operative MRI must be 
performed. 
3.1.2 Treatment Phase
[IP_ADDRESS] Randomization and Initiation of TreatmentAfter eligibility has been confirmed, subjects who are clinical ly ready to begin study treatment 
(ie, recovered from surgery) will proceed to the treatment phase of the study via a second call into 
the IVRS system. At this call, subjects w ill be randomized 1:1 to receive radiotherapy, 
temozolomide plus nivolumab or radiotherapy, temozolomide plus placebo. 
Randomization will be prospectively balanced (ie, stratified) a ccording to post-operative MRI 
finding of â€œcompleteâ€ versus â€œpartialâ€ resecti on. For the purposes of this study, a complete 
resection will be defined as â‰¤[ADDRESS_258967] tumor surgical region following surgical resection. A part ial resection is  defined as â‰¥10 mm MGMT Assay 
at Central LabEnrollment & 
Tumor 
Submission via 
CA209498Diagnosis:
Supratentorial
GBM
Randomize 
to CA209548Clinically eligible 
to enroll in 
CA209548MGMT 
Methylated or 
indeterminateMGMT
UnmethylatedClinically eligible to 
enroll in 
CA209498
Time from surgery to start RT â‰¤ 42 days
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_258968]-enhancing tumor tissue on T1 images follow ing surgical resection. Resections 
with a residual of > 5 and < 10 mm of enhancement will be defined  as partial or comp lete by [CONTACT_1275]â€™s best clinical judgment. 
The total time elapsed from definitive s urgery to initiation of RT s hould not exceed 42 days but 
may be delayed if clinically required. Typi[INVESTIGATOR_897], a delay from randomization to initiation of 
chemoradiation may be up to 7 days, or longer if clinically req uired. Subjects should begin 
nivolumab or placebo within 3 days after randomization and may b e given at any time prior to 
chemoradiation start. 
See Sections  4.5.1 and 4.5.2 for details of dosing for nivolumab and temozolomide; for an 
overview of the treatment phase, see Section 3.1.2 . 
[IP_ADDRESS] Radiotherapy
Radiation therapy s hould begin after substantial recovery from surgical resection, preferably not 
more than 42 days after surgery; however, treatment may be delay ed if clinically required. 
External-beam RT to a total dose of 60 Gy will be administered in daily doses of 2 Gy, typ ically 
on a 5 days on / 2 days off schedule as a ppropriate for sche duling, over 6-7 weeks. P atients 
considered clinically inappropriate for full dose RT (60 Gy Â±5%) are not eligible, eg, due to older 
age, tumor location. RT is administered to the post-operative t umor volume plus a 2-[ADDRESS_258969] be obtained if not part of 
the same practice group as the investigativ e study site. For adv erse events related to RT, see 
Section 6 .  
Note: Suspected progression occurring during or within 12 weeks  after RT may be 
â€œpseudoprogressionâ€; in this setting, suspected progression shou ld be confirmed prior to 
discontinuation of treatment. B MS Medical Monitor should be con sulted.
3.1.[ADDRESS_258970] from study 
treatment, including for adverse events, for maximum clin ical benefit (investigator decisio n), for 
subject request, disease progression, or another reason.
Following study unblinding, subjects who discontinue the experi mental arm will be evaluated for 
adverse events with visits at 35 days ( Â±7 days) and 115 days ( Â±7 days) after last dose; for details, 
see Table 5.1-3 and Section 6 . Subjects on placebo arm who discontinue study temozolomide 
treatment will be eva luated for adverse events with a visit at 35 days ( Â±7 days) after last dose. All 
adverse events must be documented for a minimum of 100 days aft er discontinuation of nivolumab
and for 30 days following discontinuation of temozolomide treat ment, but drug-related toxicities 
should continue to be followed until they resolve, return to ba seline, or are deemed irreversible.
Subjects will not be followe d for progression per RA NO criteria, or for survival.
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_258971] Study Access to Therapy 
At the conclusion of the study, subjects who continue to demons trate clinical benefit will be 
eligible to receive BMS supplied study drug. Study drug will be  supplied via an extension of the 
study, a rollover study re quiring approval by [CONTACT_186736] h authority and ethics co mmit tee or 
through another mechanism at the discretion of BMS. BMS reserve s the right to terminate access 
to BMS supplied study drug if any of the following occur: a) the  marketing application is rejected 
by [CONTACT_122368] h ealth aut hority; b) the study is terminated due to safety concerns; c) the  subject 
can obtain medication from a government sponsored or private he alth program; or d) therapeutic 
alternatives become available in the local market.
3.[ADDRESS_258972] be met.
3.3.1 Inclusion Criteria
1) Signed Written Informed Consent
a) Written informed consent and HIPAA authorization (applies to covered entities in the US 
only) obtained from the subject/leg al represen tative prior to performing any 
protocol-related procedures
b) Subjects must be willing and able to comply with scheduled vi sits, treatment schedule, 
laboratory testing, and other requirements of the study
2) Target Population
a) Newly-diagnosed histologically-confirmed supratentorial gliob lastoma (Grade IV 
malignant glioma by [CONTACT_78464], including gliosa rcoma) 47
i) No treatment for GBM other than surgery
ii) Post-operative baseline MRI following consensus recommendati ons51must be 
obtained prior to rando mizatio n. It is strongly recommended tha t this scan be obtained 
<72 hours or >[ADDRESS_258973].
Protocol Amendment No.: 07
Date: 02-Sep-2021 38
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
b) Substantial recovery from surgical resection 
i) No major ongoing safety issues (eg, infection requiring IV an tibiotics) following 
surgery
ii) For subjects on corticosteroids at the time of Screening: ab le to taper steroids 
(preferably discontinued). Dose at randomization must be â‰¤20 mg prednisone or â‰¤3 
mg dexamethasone daily (or equiv alent). Subjects who do not nee d corticosteroids or 
able to taper down to â‰¤20 mg prednisone.
c) As of Amendment 11, this criterion regarding screen fails from CA209498 is no longer 
applicable. 
d) Centrally confirmed (ie, third-party vendor) tumor MGMT-methylated or indeterminate 
from the CA209498 study
e) Karnofsky Performance Status of â‰¥70 (Appendix 3)
f) Clinically appropriate for concomitant temozolomide plus RT, based on investigator 
judgment 
3) Age and Reproductive Status
a) Males and Females, age â‰¥18 years old
b) Women of childbearing potential (WOCBP) must have a negative s erum or urine 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units  of HCG) within 24 hours 
prior to the start of study drug
c) Women must not be breastfeeding
d) Women of childbearing potential (WOCBP) must agree to follow instructions for 
method(s) of contraception for the duration of the study treatm ent with nivolumab/placebo 
and [ADDRESS_258974] dose of study treatment (ie, 30 day s [duration of ovulatory cycle] 
plus the time required for the investigational drug to undergo approx imately five 
half-lives).
i) As of Amendment 11, this criterion has been merged into 3.d. 
e) As of Protocol Amendment 06, this criterion refers to TMZ tre atment. Males who are 
sexually active with WOCBP must agree to follow instructions fo r method(s) of 
contraception for the duration of the s tudy treatment with TMZ a nd for [ADDRESS_258975] characteristics (SmPC), or similar document. i) Males are encouraged to seek advice on cryoconservation of spe rm prior to treatment, 
because of the possibility of irreversible infertility due to t herapy with TMZ
f) Azoospermic males and WOCBP who are continuously not heterose xually active are 
exempt from cont raceptive requir ements. However, WOCBP must still undergo pregnancy 
testing as described in this section.
Investigators shall counsel WO CBP, and male subjects who are sex ually active with WOCBP on 
the importance of pregnancy prevention and the implications of an unexpected pregnancy. 
Protocol Amendment No.: 07
Date: 02-Sep-2021 39
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Investigators shall advise on th e use of highly effective metho ds of contraception ( Appendix 4 ), 
which have a failure rate of < 1% when used consistently and co rrectly.
4) Physical and Laboratory Test Findings 
a) WBC â‰¥2,000/Î¼ L 
b) Neutrophils â‰¥1,500/Î¼ L
c) Platelets â‰¥100 x103/Î¼L
d) Hemoglobin â‰¥9.0 g/dL
e) Serum creatinine â‰¤1.[ADDRESS_258976], unless creatinine clearance (CrCl) â‰¥50 mL/min (measured 
or calculated using the Cockcroft-Gault formula) 
i) Female CrCl = (140-age in years) x weight in kg x 0.85
72 x serum creatinine in mg/dL
ii) Male CrCl = (140-age in years) x weight in kg x 1.00
72 x serum creatinine in mg/dL
f) AST â‰¤3.[ADDRESS_258977]
g) ALT â‰¤3.[ADDRESS_258978]
h) Total Bilirubin â‰¤1.[ADDRESS_258979] (except subjects with Gilbert Syndrome who may have a t otal 
bilirubin < 3.[ADDRESS_258980])
3.3.2 Exclusion Criteria
1) Target Disease Exclusions
a) Prior treatment for GBM  (other than surgical resection)
b) Recurrent GBM 
c) MGMT-unmethy lated GBM at central laboratory or tumor not avai lable
d) Biopsy-only of GBM at surgery, defined as < 20% resection of e nhancing tumor
e) Concomitant use of Gliadel Â®wafer
f) CNS hemorrhage of Grade > [ADDRESS_258981] resolved
g) Any known metastatic extracranial or leptomeningeal disease
h) Secondary GBM (ie, progression from prior low-grade or anapla stic glioma)
2) Medical History and Concurrent Diseases
a) Any serious or uncontrolled medical disorder that, in the opi [INVESTIGATOR_871], may 
increase the risk associated with study participation or st udy drug administrati on, impair 
the ability of the subject t o receive protocol therapy, or inte rfere with the interpretation of 
study results
Protocol Amendment No.: 07
Date: 02-Sep-2021 40
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
b) Subjects with an active, known or suspected autoimmune diseas e. Subjects with type I 
diabetes mellitus, hypothyroidism only requiring hormone replac ement, skin disorders 
(such as vitiligo, psoriasis or alopecia) not requiring systemi c treatment, or conditions not 
expected to recur in the absence of an external trigger are per mitted to enroll
c) Subjects with a condition requiring systemic treatment with e ither corticosteroids (> 10 mg 
daily prednisone or equivalent) or other immunosuppressive medic ations within [ADDRESS_258982] acement steroid doses 
> 10 mg daily prednisone or equivalent, are permitted in the absen ce of active autoimmune 
disease
d) Not applicable per Protocol Amendment 05.
e) Subjects with severe renal insufficiency, ie, glomerular filtr ation rate (eGFR) 
< 30 mL/min/1.73m2 (who should not receive contrast materials)
f) Subjects with history of life-threatening toxicity, including  hypersensitivity reaction, 
related to pri or imm unoglobulin treatment for another condition (except those consi dered 
unlikely to re-occur, with written approval of BMS Medical Moni tor) or any other st udy 
drug component
g) History or evidence upon physical/neurological examination of  other central nervous 
system condition (eg, seizures, abscess) unrelated to cancer, u nless adequately controlled
by [CONTACT_215311]
h) Surgical procedure < 7 days prior to study treatment (no restriction for vascular access 
device)
i) Subjects unable (eg, due to pacemaker or ICD device) or unwil ling to have a 
contrast-enhanced MRI of the head
j) Unable to swallow oral medication or any gastrointestinal disease or surgical procedure 
that may impact the absorption of study drug
k) Subjects with a hypersensitivity to Dacarbazine (DTIC)
l) Subjects who have received a live/attenuated vaccine within [ADDRESS_258983] treatment.
3) Physical and Laboratory Test Findings
a) Hepatitis B surface antigen (HBsAg, Australia antigen) positi ve, or history of active 
chronic hepatitis B
b) Hepatitis C antibody (anti-HCV) positive (except if HCV-RNA n egative), or history of 
active chronic hepatitis C 
c) Known history of positive test for human immunodeficiency vir us (HIV) or known 
acquired immunodeficiency syndrome (AIDS). NOTE: Testing for HI V must be performed 
at sites where mandated by [CONTACT_215312].: 07
Date: 02-Sep-2021 41
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
4) Allergies and Adverse Drug Reaction
a) History of allergy or hypersen sitivity to study drug componen ts
b) Prior malignancy active within the previous [ADDRESS_258984] . 
5) Other Exclusion Criteria
a) Prisoners or subjects who are involuntarily incarcerated (Note: under certain specific 
circumstances a person who has been imprisoned may be included or permitted to continue 
as a subject. Strict conditions apply and Bristol-Myers Squibb approval is required.)
b) Subjects who are compulsorily detained for treatment of eithe r a psychiatric or physical 
(eg, infectious disease) illness
Eligibility criteria for this study have been carefully conside red to ensure the safety of the study 
subjects and that the results of the study can be used. It is i mperative that subjects fully meet all 
eligibility criteria.
3.3.3 Women of Childbearing Potential
Women of childbearing potential (WOCBP) is defined as any femal e who has experienced 
menarche and who has not undergone surgical sterilization (hyst erectomy or bilateral 
oophorectomy) and is not postmenopausal. Menopause is defined a s [ADDRESS_258985] imulating hormone (FSH) level 
> 40 mIU/mL to confirm menopause.
*Females treated with hormone replacement therapy (HRT) are likely to have artificial ly 
suppressed FSH levels and may re quire a washout period in order to obtain a  physiologic FSH 
level. The duration of the washout period is a function of the type of HRT used. The duration of 
the washout period below are suggested guidelines and the inves tigators should use their judgment 
in checking serum FSH levels. 
â€¢1 week minimum for vaginal hormonal products (rings, creams, gels)
â€¢4 week minimum for transdermal products
â€¢8 week minimum for oral products
Other parenteral products may require washout periods as long a s 6 months. If the serum FSH 
level is > 40 mIU/mL at any time during the washout period, the w oman can be considered 
postmenopausal.
3.[ADDRESS_258986] systemic corticosteroids tapered as quickly as 
clinically appropriate during the screening phase, and systemic corticosteroids will be discontinued 
if possible prior to randomization. 
Protocol Amendment No.: 07
Date: 02-Sep-2021 42
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Supportive care for all disease-related or tr eatment-related adverse ev ents should be maximized 
for all subjects on this study. See Section [IP_ADDRESS] for prophylaxis of Pneumocystis pneumonia.
COVID-[ADDRESS_258987] administration of th e BMS study treatment. 
3.4.1 Prohibited and/or Restricted Treatments
Concurrent anti-neoplastic therapy, including other chemotherap y, immunotherapy, additional 
radiation therapy or investigational agents for treatment of GB M are prohibited during the 
treatment phase. Use of any additional noninvasive medical devi ce treatment of GBM 
(eg, novoTTF, Optune Â©) is prohibited. The following medications are prohibited durin g the study 
treatment (unless utilized to treat a drug related adverse even t):
â€¢Immunosuppressive agents
â€¢Immunosuppressive doses of systemic corticosteroids (except as stated in Section 3.4.3 ) 
â€¢Any live/attenuated vaccine (eg, live COVID- 19, varicella, zos ter, yellow fever, rotavirus, oral 
polio and measles, mumps, rubella [MMR]) during treatment and until [ADDRESS_258988] dose.
3.4.2 Other Restrictions and Precautions
Subjects with a condition requiring systemic treatment with eit her corticosteroids (> 10 mg daily 
prednisone per day or equivalent) or other immunosuppressive me dications (including within 
14 days of rando mization) a re excluded. Subjects continuing to require supra physiologic steroids 
(prednisone > 20 mg daily or > 3 mg dexamethasone per day or equ ivalent) for increased intra 
cranial pressure may not be randomized. Inhaled or topi[INVESTIGATOR_215278] > 10 mg daily prednisone per day or equivalent are permitted in the absence of active 
autoimmune disease.
[IP_ADDRESS] Imaging Restriction and Precautions
Study-related MRI imaging of the brain will be performed using contrast materials. It is the local 
imaging facilityâ€™s responsibility t o determine, base d on participant attributes  (eg, allergy history, 
diabetic history, and renal status), the appropriate imaging modality and contrast regimen per 
imaging study. Imaging contraindications and contrast risks are to be considered in this 
assessment. Participants with renal insufficiency are to be ass essed as to whether or not they should 
receive contrast and if so, which contrast agent and dose is ap propriate. Specific to MRI, 
participants with severe renal insufficiency (ie, estimated glo merular filtration rate 
(eGFR) < 30 mL/min/1.73 m2) are at increased risk of nephrogenic s ystemic fibrosis, therefore 
MRI contrast is contraindicated. In addition, participants may be excluded from MRI if they have 
tattoos, metallic implants, pacemakers, etc. This will be outlined in the image acquisition manual.
Gentle hydration before and after IV contrast should follow loc al standard of care. The ultimate 
decision to perform MRI in an indi vidual participant in this study rests with the site radiologist, 
the investigator, and standards set by [CONTACT_215313].
Protocol Amendment No.: 07
Date: 02-Sep-2021 43
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
In accordance with TMZ labeling, valproic acid should not be us ed concomitant with TMZ; at 
investigator discretion, alternative anticonvulsants should be used.
3.4.3 Permitted Therapy
Subjects are permitted the use of topi[INVESTIGATOR_2855], ocular, intra-articu lar, intranasal, and inhalational 
corticosteroids (with minimal systemic absorption). Adrenal rep lacement steroid doses > 10 mg 
daily prednisone are permitted. A brief (less than 3 weeks) cou rse of corticosteroids for 
prophylaxis (eg, contrast dye allergy) or for treatment of non-a utoimmune conditions 
(eg, delayed-type hypersensitivity r eaction cause d by a contact [CONTACT_20435]) is permitted.
Steroid use should be  minimized prior to ra ndomization. Systemic corticosteroid use or 
physiologic rep lacement doses of steroids are permitted, even if > 20 mg/day pre dnisone 
equivalents, for: a) treatment-related AEs; b) symptoms related to GBM, including suspected 
tumor flare or pse udoprogression; or c) treatment of non-autoimm une conditions (eg, prophylaxis 
for contrast dye allergy, contact [CONTACT_180325]). Details re garding corticosteroid use prior to and 
during the study w ill be co llected (name [CONTACT_2100], doses utilized, start and stop dat es, 
frequency of use, route of administration). Information regardi ng concomitant corticosteroid use 
may be analyzed with regard to study outcome measures.
Subjects requiring chronic treatment with corticosteroids may be treated with histamine-2-receptor 
antagonists or proton pump inhibitors as prophylaxis for potent ial gastrointestinal adverse 
reactions (ulceration, perforation, hemorrhage) unless otherwis e contraindicated.
Concomitant medications are recorded at baseline and throughout  the treatment phase of the study 
in the appropriate section of the CRF. All medications (prescri ptions or over the counter 
medications) continued at the start of the study  or started during the study and different from the 
study drug must be doc umented in the concomitant therapy s ection of the  CRF.
3.[ADDRESS_258989] (and non-inve stigational product at the 
discretion of the investigator) for a ny of the following reasons:
â€¢Disease progression, except as described in Section [IP_ADDRESS]
â€¢Unacceptable toxicity requiring discontinuation of both TMZ and  nivolumab/placebo, see 
Sections [IP_ADDRESS] and [IP_ADDRESS]
â€¢Maximum clinical benefit, as determined by [CONTACT_1697]
â€¢Subjectâ€™s request to stop study treatment (other than for an AE )
â€¢Any clinical adverse event (AE), laboratory abnormality or intercurrent illness which, in the 
opi[INVESTIGATOR_871], indicates that continued participation in the study is not in the best 
interest of the subject, see Sections [IP_ADDRESS] and [IP_ADDRESS]
â€¢Termination of the study by [CONTACT_414]-Myers Squibb
â€¢Loss of ability to fr eely provide consent through imprisonment or involuntarily inca rceration 
for treatment of either a psychiatric or physical (eg, infectio us disease) illness
â€¢Initiation of other antineoplastic treatment
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_258990] cases, study d rug will  be permanently discontinued in an appropriate manner. Please 
call the Spons or or designee within 24 hours of awareness of the  pregnancy. If the investigator 
determines a possible favorable benefit/risk ratio that warrant s re-initiation of study drug, after 
termination of pregnancy and if allowed by [CONTACT_427], a discussion between the investigator 
and the BMS Medical Monitor/designee must occur.
All subjects who discontinue study drug should comply with prot ocol specified follow-up 
procedures as outlined in Section [ADDRESS_258991]-treat ment study follow-up or loses the 
ability to consent fr eely (ie, is imprisoned or involuntarily i ncarcerated for the treatment of either 
a psychiatric or physical illness).
If study drug is discontinued prior to the subjectâ€™s completion  of the study, the reason for the 
discontinuation must be documented in the subjectâ€™s medical rec ords and entered on the 
appropriate case report form page.
3.[ADDRESS_258992] that survival data be collected 
on all treated/ra ndomized subjects outside of the [ADDRESS_258993] with him /her or persons previously 
authorized by [CONTACT_20439]. Subjects sho uld notify the investigator of the 
decision to withdraw consent from future follow-up in writing , if possible. The withdrawal of 
consent should be explained in detail in the medical records by  [CONTACT_093], as to whether the 
withdrawal is from further treatment with study drug only or al so from study procedures and/or 
post treatment study follow-up, and entered on the appropriate CRF page. In the event that vital
status (whether the subject is alive or dead) is being measured, publicly available information 
should be used to determine vital status only as appropriately directed in accordance with local 
law.
3.6.[ADDRESS_258994] after a minimu m of three documented phone calls,
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_258995]â€™s medical records. If it is  determined that the subject has died, 
the site will use permissible local methods to obtain the date a nd cause of death.
If investigatorâ€™s use of third-party representative to assist i n the follow- up portion of the study has 
been included in the subjectâ€™s informed consent, then the inves tigator may use a Sponsor-retained 
third-party representative to assist site staff with obtaining subjectâ€™s contact [CONTACT_61860]-up po rtion of the study. The site staff and 
representative will consult publicly available sources, such as  public health registries and 
databases, in order to obtain updated contact [CONTACT_3031]. If after all attempts, the subject remains 
lost to follow-up, then the last known alive date as determined by [CONTACT_093] s hould be 
reported and documented in the subjectâ€™s medical records.
Protocol Amendment No.: 07
Date: 02-Sep-2021 46
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
4 STUDY DRUG
Study drug includes both Investigational [Medicinal] Product (I P/IMP) and Non-investigational Medicinal Product (Non-IP/Non-IM P) 
and can consist of the following:
Table 4-1: Study Drugs for CA209548
Product Description /
Class and Dosage FormPotencyIP/
Non-IMPBlinded or 
Open LabelPackaging/ AppearanceStorage Conditions
(per label)
Nivolumab
[BMS-936558-01] 
Solution for Injectiona100 mg 
(10 mg/mL)IP Open-label10 mL per vial (5 or 10 vials/carton)
Clear to opalescent colorless to pale yellow liquid. May 
contain particles2 to 8 Â°C. Protect 
from light and 
freezing
PlaceboaN/A IP N/A Not provided by [CONTACT_215314]20 mg IP Open-labelWallet/blister card containing 5 capsules
White opaque cap and body, imprinted in yellow i nk. The 
cap is imprinted with â€˜891.â€™ The body is imprinted with 
â€˜20 mgâ€™ and two stripes.Do not store above 
25 Â°C.
Temozolomide Capsulesb100 mg IP Open-labelWallet/blister card containing 5 capsules
White opaque cap and body, imprinted in pi[INVESTIGATOR_215279]. The 
cap is imprinted with â€˜892.â€™ The body is imprinted with 
â€˜100 mgâ€™ and two stripes.Do not store above 
25 Â°C.
Temozolomide Capsulesb140 mg IP Open-labelWallet/blister card containing 5 capsules
White opaque cap and body, imprinted in blue ink. The 
cap is imprinted with â€˜929.â€™ The body is imprinted with 
â€˜140 mgâ€™ and two stripes.Do not store above 
25 Â°C.
aThe term â€œopen-labelâ€ refers to the medication a s it is upon receipt at the pharmacy. The trial will be conduct ed in a single-blinded fas hion, ie, nivolumab/placebo 
blinded to site staff and patients. May be labeled  as either â€œBMS-936558-01â€ or â€œNivolumab.â€
bThese products may be obtained by [CONTACT_215315]. In these cases, 
products may be a different pack size/potency t han listed in the table. These products should be prepared/stor ed/administered in accordance with the package 
insert or summary of product characteristics.
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_258996] in some regions, is 
defined a pharmaceutical form of an active substance or placebo  being tested or used as a reference 
in a clinical study, including products already with a marketin g authorization but used or 
assembled (formulated or packaged) differently than the authori zed form, or used for an 
unauthorized indication, or when used to gain further informati on about the authorized form.
The investigational product should be stored in a secure area a ccording to local regulations. It is 
the responsibility of the investigator to ensure that investiga tional product is only dispensed to 
study subjects. The investigational product must be dispensed o nly from official study sites by 
[CONTACT_20443]. 
In this protocol, investigational products are nivolumab (BMS-9 [ZIP_CODE]), nivolumab placebo
(0.9% sodium chloride for in jection or 5% dextrose for inject ion), and temozolomide. Althoug h 
not a medicinal product, Radiation Therapy is also considered p art of study treatment.
4.[ADDRESS_258997] storage manager should ensure that the study drug is  stored in accordance with the 
environmental conditions (temperature, light, and humidity) as determined by [CONTACT_20444]. If concerns 
regarding the quality or appearance of the study drug arise, th e study drug should not be dispensed 
and contact [CONTACT_20445].
Study drug not supplied by [CONTACT_20446] h the package insert.
Please refer to Section 9.2.2 for guidance on IP records and documentation. 
Infusion-related supplies (eg, IV ba gs, in-line filters (0.2-1. 2 micron), 0.9% NaCl or 5% Dextrose 
solution) will not be supplied by [CONTACT_61864].
For non-inves tigational product, if marketed product is utilize d, it should be stored in accordance 
with the package insert, summary of product characteristics (Sm PC), or similar.
Please refer to the current version of the Investigat or Brochure and/or pharmacy reference sheets 
for complete storage, handling, dispensing, and infusion inform ation for nivolumab 
(BMS-936558).46
4.3.1 Nivolumab (BMS-936558)
For details regarding drug storage, preparation, administration , and use time please refer to the 
nivolumab (BMS-936558) Investigator Brochure46and/or pharmacy reference sheets.
Protocol Amendment No.: 07
Date: 02-Sep-2021 48
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
4.3.2 Temozolomide
For countries in which BMS is providing packaged/labeled temozo lomide, please refer to package 
insert, summary of product characteristics (SmPC), or similar document for details regarding drug 
preparation, administration and use t ime.
For countries where local sourcing of temozolomide is permitted , product should be stored, 
prepared and administered in accordance to the package insert, summary of product characteristics 
(SmPC) or similar document.
4.[ADDRESS_258998] be enrolled into the CA209498 study by [CONTACT_215316] (IVRS) to obtain the subject number. The subject identif ication number in the CA209498 
study will become the study numb er for the CA209548 study. Ever y subject that signs the informed 
consent form must be assigned a subject num ber in IVRS. The investigator or designee will register 
the subject for enrollment by [CONTACT_215317]. The 
following information is required for enrollment:
â€¢Date that informed consent was obtained
â€¢Date of birth of subject
â€¢Gender (at birth) of subject
â€¢Patient ID from the CA209498 study
Once enrolled in IVRS, enrolled subjects who meet all eligibili ty criteria and are clinically ready 
to begin treatment w ill be ra ndomized through the IVRS. Central lab confirmation of MGMT-
methylated or indeterminate must be received prior to the IVRS randomization call. The following 
information is required for randomization: 
â€¢Subject number
â€¢Date of birth of subject
â€¢Extent of tumor resection: Complete or Partial
Subjects meeting all eligibility criteria will be randomized in a 1:[ADDRESS_258999] dose of nivolumab is to be 
administered within 3 days of  randomization. Treatment details a re described below. 
Protocol Amendment No.: 07
Date: 02-Sep-2021 49
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Table 4.5-1: Selection and Timing of Dose
Drug DoseFrequency of 
administrationRoute of 
administrationDuration
Nivolumab/
Placebo 
(BMS-936558)240 mg
480 mg, after 8 doses Every 2 weeks, 
for 8 doses
Every 4 weeks after 
8 doses30 minute 
intravenous 
(IV)Until progression, 
unacceptable 
toxicity, or 
discontinuation from 
treatment
Temozolomide 
(TMZ)75 mg/m2daily during 
RT 
then 150 mg/m2D1-5 
for C1 
and increased to 
200 mg/m2D1-[ADDRESS_259000] day of RT 
(not to exceed 49 days) 
then 4 week break 
followed by [CONTACT_215318] 5 days every 28 days 
x 6 cyclesaOral (PO)Until completion of 
dosing, progression, 
unacceptable 
toxicity or 
discontinuation from 
treatment
aAdditional cycles of temozolomide are permitted for subjects en rolled in Japan as well as others with written 
permission of Sponsor 
Treatment modifications (eg, dose delay, reduction, or disconti nuation) will be based on specific 
laboratory and adverse event criteria, as described in Sections 4.5.1 and 4.5.2 . If the toxicity is 
considered related to either TMZ or nivolumab/placebo, both may be delayed, based on 
investigator judgment. However, if the toxicity is related to o ne or the other, then that one should 
be delayed or discontinued as appropriate. If the subject conti nues on either study drug, the visit 
schedule and assessments will continue as described in Table 5.1-2. 
4.5.1 Nivolumab/Placebo Dosing
To reduce bias, this study is blinded for the investigational a gent. Therefore, all provisions for 
dosing and dose modification apply equally to the [ADDRESS_259001] will be unblinded t o randomized arm; matched infusio ns (0.9% sodium chloride 
for injection or 5% dextrose for injection) will be provided to  subjects on the control arm.
Nivolumab (BMS- 936558) is to be a dministered as an IV infusion over 30 minutes. At the end of 
the infusion, flush the line with a sufficient quantity of 5% d extrose solution or normal saline.
[IP_ADDRESS] Nivolumab/Placebo Dose and ScheduleSubjects should begin study treatment within [ADDRESS_259002]. 
Continuation of nivo lumab treatment with suspected progression is permitted; see Section [IP_ADDRESS] . 
Treatment will continue until discontinuation from study tr eatment for any of the criteria listed in 
Sections 3.5 or [IP_ADDRESS] . 
Protocol Amendment No.: 07
Date: 02-Sep-2021 50
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Subjects may be dosed no less than 12 days from the previous do se during Q2W cycles. A dose 
given more than 3 days after the intended dose date will be cons idered a delay. For Q4W dosing 
cycles, subjects may be dosed within a Â±3 day window. Subsequent dosing should be based on 
the actual d ate of administration of the previous dose of drug. Note: The 48 0 mg dosing starts at 
Cycle 9, which begins 2 weeks after the start of Cycle 8 (Week 17 in the absence of delays). 
There are no premedications recommended for nivolumab on the first cycle.
Subjects should be monitored for i nfusion reactions during nivo lumab administration. If an acute 
reaction is noted, subjects should be managed according to Section [IP_ADDRESS] .
Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the 
subject tolerates treatment. Nivolumab/placebo should be delaye d (see Section [IP_ADDRESS] ) for 
toxicities considered at least  possibly-r elated to ni volumab. I f toxicity is related to TMZ only, then 
only that agent should be interrupted; see Section [IP_ADDRESS] . If the toxicity is considered related to 
either TMZ or nivolumab/placebo, both may be delayed, based on i nvestigator judgment.
No incompatibilities  have been observed between nivolumab for i njection and polyvinyl chloride 
(PVC), non-PVC/non-DHEP (di(2ethylhexyl)phthalate) IV components  or glass bottles.
[IP_ADDRESS] Dose Modifications for Nivolumab/Placebo
Dose modification is not allowed for nivolumab; for dose delay,  see Section  [IP_ADDRESS].
[IP_ADDRESS] Dose Delay Criteria for Nivolumab/PlaceboTumor assessments should continue per protocol schedule, even i f dosing is delayed.
Nivolumab administration should be delayed for the following:
â€¢Grade 2 non-skin, drug-related adverse event, with the exception  of fatigue
â€¢Grade  [ADDRESS_259003], ALT and/or Total Bilirubin abnormalities
â€¢Grade 3 skin, drug-related adverse event
â€¢Grade 3 drug-related laboratory abnormality with the following exceptions:
âˆ’Grade 3 lymphopenia or asymptomatic amylase or lipase does not require dose delay
âˆ’Grade â‰¥[ADDRESS_259004]/ALT or total bilirubin will require dose discontinuation (See Section  
[IP_ADDRESS] ).
â€¢Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the investigator, warrants delaying the dose of study medicatio n.
â€¢Severe acute respi[INVESTIGATOR_6507] 2(SARS-CoV-2) infec tion, either confirmed or 
suspected
Subjects who require delay of nivolumab should be re-evaluated weekly or more frequently if 
clinically ind icated. Nivolumab dosing can be resumed on the es tablished dosing schedule (q2 or 
q4 weeks) when retreatment criteria are met ( Section [IP_ADDRESS] ). 
Protocol Amendment No.: 07
Date: 02-Sep-2021 51
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
[IP_ADDRESS] Criteria to Resume Dosing for Nivolumab/Placebo
Subjects may resume treatment with study drug when the drug-rel ated AE(s) resolve(s) to 
Gradeâ‰¤1 or baseline value, with the following exceptions:
â€¢Subjects may resume treatment in the presence of Grade 2 fatigu e
â€¢Subjects who have not experienced a Grade 3 drug-r elated skin AE may re sume treatment in 
the presence of Grade 2 skin toxicity
â€¢For subjects with Grade [ADDRESS_259005], A LT, and/or total bilirubin abno rmalities, dosing may resume 
when laboratory values return to bas eline and management with corticosteroids, if needed, is 
complete
â€¢Subjects with combined Grade [ADDRESS_259006]/ALT AND total bilirubin value s meeting 
discontinuation parameters ( Section [IP_ADDRESS] ) should have treatment permanently discontinued
â€¢Drug-related pulmonary tox icity, dia rrhea or colitis must have resolved to baseline before 
treatment is resumed. Subjects with persistent Grade [ADDRESS_259007] 1 month may be eligible for retreatm ent if discussed with and 
approved by [CONTACT_104129]
â€¢Subjects with drug-related endocrinopathies adequately controll ed with only physiologic 
hormone replacement may resume treatment after consultation wit h the BMS Medical 
Monitor. Adrenal insufficiency requires discontinuation regardl ess of control with hormone 
replacement.
â€¢Subjects with SARS-CoV-2 infection (either confirmed or suspecte d) may resume treatment 
after all of the following:
âˆ’1) at least 10 days (20 days for severe/critical illness) have passed since symptoms first 
appeared or positive test result (e.g. RT-PCR or viral antigen) , 2) resolution of acute 
symptoms (including at least [ADDRESS_259008] fev er without fever reducing 
medications), 3) evaluatio n by [CONTACT_215319] a higher risk of receiving investigational treatment, and 
4) consultation by [CONTACT_215320]. For suspected cases, tr eatment may also resume if 
SARS-CoV-2 infection is ruled-out and other criteria to resume treatment are met.
[IP_ADDRESS] Treatment Discontinuation Criteria for Nivolumab/Placebo
Nivolumab treatment should be permanently discontinued for the following: 
â€¢Any Grade 2 drug-related uveitis, eye pain or blurred vision tha t does not respond to topi[INVESTIGATOR_61780] 1 severity within the re- treatment period OR requires 
systemic treatment.
â€¢Any Grade 3 non-ski n, drug-related adve rse event lasting > [ADDRESS_259009] ions, and endocrinopathies:
âˆ’Grade 3 drug-related uveitis, pne umonitis, bronchospasm, neurol ogic toxicity, 
myocarditis, hypersensitivity reaction, or infusion reaction of  any duration requires 
discontinuation
Protocol Amendment No.: 07
Date: 02-Sep-2021 52
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
âˆ’Grade 3 drug-related endocrinopathies adequately controlled wit h only physiologic 
hormone replacement do not require discontinuation. Adrenal ins ufficiency requires 
discontinuation regardless of  control with hormone replacement.  
âˆ’Grade 3 drug-related laboratory a bnormalities do not require treatment discontinuation 
except:
â™¦Grade 3 drug-related thrombocytopenia > 7 days or associated wi th bleeding requires 
discontinuation
â™¦Grade â‰¥[ADDRESS_259010], A LT, or Total Bilirubin requires discontinu ation*
â€¢*In most cases of Grade [ADDRESS_259011] or ALT elevation, study drug(s) w ill be permanently 
discontinued. If the investigator determines a possible favorab le benefit/risk ratio that warrants 
continuation of study drug(s), a discussion between the investi gator and the BMS Medical 
Monitor/designee must occur. 
â™¦Concurrent AST or ALT > [ADDRESS_259012] and Total Bilirubin > [ADDRESS_259013]
â€¢Any Grade 4 drug-related adverse event or laboratory abnormalit y (including but not limited 
to creatinine, AST, ALT, or Total Bilirubin), except for the fo llowing events which do not 
require discontinuation:âˆ’Grade 4 neutropenia â‰¤7 days
âˆ’Grade 4 lymphopenia or leukopenia or asymptomatic amylase or lip ase
âˆ’Isolated Grade 4 electroly te imbalances/abnormalities that are not associated with clinical 
sequelae and are corrected with supplementation/appropriate management w ithin 72 hours 
of their onset
âˆ’Grade 4 drug-related endocrinopathy adverse events, hyper- or hypothyroidism, or glucose 
intolerance, which resolve or are adequately controlled with ph ysiologic hormone 
replacement (corticosteroids, thyroid hormones) or glucose-cont rolling agents, 
respectively, may not require discontinuation afte r discussion with an d approval from the 
BMS Medical Monitor. 
â€¢Any event that leads to delay in dosing lasting > 6 weeks from the previous dose requires 
discontinuation, with the following exceptions:
âˆ’Dosing delays to allow for prolonged steroid tapers to manage d rug-related adverse events 
are allowed. 
âˆ’Dosing delays lasting > [ADDRESS_259014] with a dosing del ay lasting > [ADDRESS_259015] be c onsulted. Tum or assessments should continue as per protocol even 
if dosing is delayed. Periodic study visits to assess safety an d laboratory studies should also 
continue every 6 weeks or more fr equently if clinically indicat ed during such dosing delays.
Protocol Amendment No.: 07
Date: 02-Sep-2021 53
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
â€¢Any adverse event, laboratory abnormality, or intercurrent illn ess which, in the judgment of 
the Investigator, presents a substantial clinical risk to the s ubject with continued nivolumab 
dosing.
â€¢Following study treatment unb linding, a decision by [CONTACT_215321] g physician and the subject to 
discontinue treatment.
[IP_ADDRESS] Continuing Nivolumab/Placebo with Suspected Progression
Accumulating evidence indicates that a minority of subjects tre ated with immunotherapy may 
derive clinical benefit despi[INVESTIGATOR_215280], eg, due to inflammatory 
reaction simulating progression (â€œtumor flareâ€ or pseudoprogres sion). At the discretion of the 
investigator, subjects may continue nivolumab in the setting of  suspected progression until 
progression is confirmed. [Note: this is not the same as confirmation of progression occurring 
within 12 weeks after RT, which is a component of RANO criteria .] Communication with the BMS 
Medical Monitor is strongly encouraged. If the investigator bel ieves that the subject continues to 
derive clinical benefit by [CONTACT_43893], the subject sho uld continue assessments according 
to Table 5.1-2 .
Subjects may continue nivolumab beyond suspected progression only if they meet the following 
criteria:
â€¢Subject is tolerating nivolumab
â€¢Treatment will not delay intervention to prevent imminent compl ications, eg surgery for relief 
of symptomatic intracranial mass effect 
â€¢Investigator-assessed overall clinical benefit
Radiographic assessment should be repeated after suspected prog ression as clinically required in 
order to determine whether there has been a decrease in the tum or size  or continued progression. 
If possible, perfusion images s hould also be obtained. All MRI scans should be submi tted to the 
imaging vendor as soon as possible. 
Re-operation should be considered, if lesion is surgically acce ssible, to differentiate immune-
treatment effects from progression. The BMS Medical Monitor sho uld be consulted. Potential for 
clinical benefit s hould be b alanced by [CONTACT_2085] j udgment as to whether the subject is clinically 
deteriorati ng and unlikely to receive benefit from continued treatment wit h nivolumab. Nivolumab 
treatment should be discontinued  permanently upon confirmation of RANO-assessed progression 
but prolonged observation (eg, 3 months) may be required, as su ggested in Okada et al.48
[IP_ADDRESS] Management Algorithms for Immuno-Oncology Agents
Immuno-oncology (I-O) agents are associated with AEs that can d iffer in severity and duration 
than AEs caused by [CONTACT_20451]. Nivolumab is cons idered an immuno-oncology agent 
in this protocol. Early recognition and management of AEs assoc iated with immuno oncology 
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_259016] 
investigators in assessing and managing the following groups of  AEs:
â€¢Gastrointestinal
â€¢Renal
â€¢Pulmonary
â€¢Hepatic
â€¢Endocrinopathy
â€¢Skin
â€¢Neurological
â€¢Myocarditis
The above algorithms are found in Appendix 1  and in the nivolumab Investigator Brochure.49
[IP_ADDRESS] Treatment of Nivolumab/Placebo-Related Infusion Reactions
Since nivolumab contains only human immunoglobulin protein sequ ences, it is unlikely to be 
immunogenic and induce infusion or hypersensi tivity reactions. However, if such a reaction were 
to occur, it might manifest with fever, chills, rigors, headach e, rash, pruritus, arthralgias, 
hypotension, hypertension, bronchospasm, or other allergic-like  reactions. All Grade [ADDRESS_259017] udy medical monitor and reported 
as an SAE if it meets the criter ia. Infusion reactions should b e graded according to NCI CTCAE 
(Version 4.03) guidelines.
Treatment recommendations are provided below and may be modifie d based on local treatment 
standards and guidelines, as appropriate:For Grade 1 symptoms: (mild reaction; in fusion interrupti on not indicated; intervention not 
indicated):
â€¢Remain at bedside and monitor subject until recovery from sympt oms. The following 
prophylactic prem edications are recomme nded for future i nfusions: diphe nhydramine 50 mg 
(or equivalent) and/or acetaminophen/pa racetamol [ADDRESS_259018] 30 minutes before 
additional nivolumab/placebo administrations.
For Grade 2 symptoms: (moderate reaction required therapy or infusion inter ruption but responds 
promptly to symptomatic treatment (eg, antihis tamines, non-steroidal anti-inflammatory drugs, 
narcotics, corticosteroids, bronchodilators, IV fluids); prophylactic medications indicated for 
â‰¤24 hours):
â€¢Stop the nivolumab/placebo i nfusion, begin an IV infusion of normal saline, and tr eat the 
subject with diphenhydramine 50 mg IV (or equivalent) and/or ac etaminophen/paracetamol 
325 to 1000 mg; remain at bedside and monitor subject until reso lution of symptoms. 
Corticosteroid and/or bronchodilator therapy may also be admini stered as appropriate. If the 
infusion is interrupted, then restart the i nfusion at 50% of the original infusion r ate when 
Protocol Amendment No.: 07
Date: 02-Sep-2021 55
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
symptoms resolve; if no further complications ensue after 30 mi nutes, the rate may be 
increased to 100% of the original infusion r ate. Monitor subject closely. If symptoms recur, 
then no further nivolumab/placebo will be administered at that visit.
â€¢For future infusions, the following prophy lactic premedications are recommended: 
diphenhydramine 50 mg (or equiv alent) and/or acetaminophen/para cetamol [ADDRESS_259019] 30 minutes before nivolumab/pla cebo infusions . If necessary, 
corticosteroids (up to 25 mg of SoluCortef  or equivalent) may be used.
For Grade 3 or 4 symptoms: (severe reaction, Grade 3: prol onged [ie, not rapi[INVESTIGATOR_52202]/or brief interruption of infusion]; recurrence of symptoms following 
initial improv ement; hospi[INVESTIGATOR_14138] (e g, renal impairment, 
pulmonary infiltrates). Grade 4: Life threatening; pressor or v entilatory support indicated):
â€¢Immediately discontinue infusion o f nivolumab/p lacebo. Begin an IV infusion of normal s aline 
and treat the sub ject as follows: Reco mmend bronchodilators , epi[INVESTIGATOR_238] 0.2 to 1 mg of a 
1:1000 solution for subcutane ous administrati on or 0.1 to 0.25 mg of a 1:10,000 solution 
injected slowly for IV administration, and/or diphenhydramine 5 0 mg IV with 
methylprednisolone 100 mg IV (or equivalent), as needed. Subject  should be monitored until 
the Investigator is comfortable that the symptoms will not recu r. Nivolumab/placebo w ill be 
permanently discontinued. Investigators should follow their ins titutional guidelines for the 
treatment of anaphylaxis. Remain at bedside and monitor subject  until recovery of the 
symptoms.
In case of late-occurring hypersen sitivity symptoms (eg, appear ance of a localized or generalized 
pruritus within 1 week after treatment), symptomatic treatment may be given (eg, oral 
antihistamine or corticosteroids).
4.5.2 Temozolomide Dosing
[IP_ADDRESS] Temozolomide Dose and Schedule
Subjects will be administered temozolomide (TMZ, TemodarÂ®) daily during RT and as 
maintenance therapy for 6 cycles. TMZ dosing will be performed according to investigator 
judgment; the following guidance is drawn from published literature.
TMZ will be dosed at 75 mg/m2once per day continuously throughout RT, typi[INVESTIGATOR_116389] 42 days 
and with a maximum of 49 days. See Table [IP_ADDRESS]-1 for dose modifications during concomitant 
RT+TMZ dosing. After completion of RT, there will be a 4 week br eak. Subjects w ill receive 
6 cycles of temozolomide daily x 5 days every 28 days. The timing of maintenance TMZ cycles 
may be adjusted for clinical convenience, eg, to coincide with n ivolumab/placebo dosing.
Protocol Amendment No.: 07
Date: 02-Sep-2021 56
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Table [IP_ADDRESS]-1: Dose Levels for Maintenance TMZ Monotherapy
Dose Level TMZ Dose in mg/m2/day Notes
-1 100 mg/m2/day Reduction for prior toxicity
0 150 mg/m2/day Dose during first maintenance cycle
1 200 mg/m2/dayDose during subsequent maintenance TMZ in absence of TMZ-
related toxicity
Source: adapted from Temodar Â®package insert (PI)
In the first maintenance cycle, TMZ is given at a dose of 150 mg /m2, and then increased to 
200 mg/m2in Cycle 2 as follows: If, during the first cycle, all non-hema tologic AEs observed were 
Grade â‰¤2 (except alopecia, nausea and vomiting) and with platelets â‰¥100 x 109/L and 
ANCâ‰¥1.5 x109/L, then the temozolomide dose should be escalated to dose level 1, and this dose 
should be used as the starting dose for subsequent cycles. Doses  of TMZ are not precise but are 
adjusted based on tolerance; rounding of up to 10% is entirely acceptable.  
If treatment after Cycle  1 has to be delayed because of ongoing non-hematologic AEs of Gradeâ‰¥2, 
then no escalation is possible. If the dose was not escalated a t Cycle 2, then the dose should not be 
escalated in further cycles based on adverse events (see Table [IP_ADDRESS]-2 ). If there was a prior dose 
reduction or discontinuation during the concomitant period with  RT, then dose -1 should be the 
starting dose for subsequent cycles. Table [IP_ADDRESS]-1 describes dose levels during temozolomide 
maintenance.
As noted in Section [IP_ADDRESS] , if toxicity is related to TMZ only, then only that agent shou ld be 
interrupted. If the toxicity is considered related to either TMZ  or nivolumab/placebo; however, 
both may be delayed, based on investigator judgment.
[IP_ADDRESS] Criteria to Start Temozolomide Maintenance Cycles 
Maintenance treatment begins fo llowing a 4-week treatment break after RT. TMZ treatment may 
begin if blood count (obtained within the pri or 3 days) shows ANC â‰¥1.5 x 109/L, platelet count 
â‰¥100 x 109/L and any Grade â‰¥3 non-hematologic AE (except alopecia) must have resolved to 
Gradeâ‰¤1). If AEs persist, treatment should be delayed by [ADDRESS_259020] still not resolved to â‰¤Grade 1: then a ny further main tenance 
treatment with temozolomide should be discontinued.
[IP_ADDRESS] Dose Modifications or Discontinuation for Temozolomide
TMZ dosing will be performed according to investigator judgment; the following guidance is 
drawn from published literature.
Protocol Amendment No.: 07
Date: 02-Sep-2021 57
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Table [IP_ADDRESS]-1: Temozolomide Dose Modification Guidelines During Concomitant 
Radiotherapy and TMZ Dosing
Laboratory Value/Clinical Criteria: Dose Modification: Additional  Information:
ANC:
â‰¥0.5 and < 1.5 x109/L Delay TMZ Dosing Continue when â‰¥1.5 x109/L
< 0.5 x109/L Discontinue TMZ May restart at dose -1 in maintenance
Platelets:
â‰¥10 and < 100 x 109/L Delay TMZ Dosing Continue when â‰¥100 x 109/L
< 10 x 109/L Discontinue TMZ May restart at dose -1 in maintenance
Any Non-Hematologic Toxicity (except alopecia, nausea, vomiting)
CTC Grade 2 Delay TMZ dosingContinue when â‰¤CTC Grade 1 
(except for alopecia, nausea, vomiting)
CTC Grade 3 or 4 Discontinue TMZ dosing May restart at dose -1 in  maintenance
Source: adapted from Temodar Â®package insert (PI)
Table [IP_ADDRESS]-2: Temozolomide Dose Modification Guidelines During Maintenance 
TMZ Dosing
Laboratory Value/
Clinical Criteria:Dose Modificationa: Additional Information:
ANC:
< 1.0 x109/LReduce TMZ Dosing by 1 
dose level per Table 5.4.2-1
< 0.5 x109/L Discontinue TMZ dosingIf Dose Level -1 (100 mg/m2) still results in 
unacceptable toxicity
Platelets:
â‰¥10 and < 100 x 109/LReduce TMZ Dosing by 1 
dose level per Table 5.4.2-1
< 10 x 109/L Discontinue TMZ dosingIf Dose Level -1 (100 mg/m2) still results in 
unacceptable toxicity
Any Non-Hematologic Toxicity (except alopecia, nausea, vomiting )
CTC Grade 3Reduce TMZ Dosing by 1 
dose level per Table 5.4.2-1
CTC Grade 4 Discontinue TMZ dosingIf Dose Level -1 (100 mg/m2) still results in 
unacceptable toxicity or the same Grade [ADDRESS_259021] non-
hematologic toxicity during  the prior cycle.
Source: adapted from Temoda r package insert (PI)
Protocol Amendment No.: 07
Date: 02-Sep-2021 58
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
[IP_ADDRESS] Supportive Care during Temozolomide
Subjects should be treated to r eceive prophylaxis against Pneum ocystis pneumonia (inhaled 
pentamidine [preferred], dapsone or oral trimethoprimâ€“sulfametho xazole) during concomitant 
treatment wit h RT plus TMZ and may be continued during maintena nce at investigator discretion. 
Details regarding prophylactic agent use will be collected as co ncomitant medications.
Antiemetic prophylaxis with metoclopramide or a 5-hydroxytrypta mine [ADDRESS_259022] is allowed 
prior to treatment with temozolomide.
4.6 Blinding/Unblinding
The blinding strategy selected for the protocol is the single-blinding design, also called 
â€œsite-subject blinded.â€50The subjects, investigator, and site staff will be blinded to th e study 
therapy administered. Each investigative site must assign an un blinded pharmacist/designee. 
Designated staff of BMS Research & Development will be unblinde d to facilitate drug supply and 
safety monitoring.  
Blinding of treatment assignment is critical to the integrity o f this clinical study. However, in the 
event of a medical emergency or pregnancy in an individual subj ect in which knowledge of the 
investigational product is critical to the subjectâ€™s management , the blind for that subject may be 
broken by [CONTACT_093]. The subjectâ€™s safety takes priority  over any other considerations in 
determining if the treatment assignment should be unblinded.
Before breaking the blind of an individual subjectâ€™s treatment,  the investigator should determine 
that the unblinded information is necessary, ie, that it w ill alter the sub jectâ€™s immediate 
management. In many cases, particularly when the emergency is c learly not related to the 
investigation al product, the  problem may be properly managed by [CONTACT_82745]. It is highly desirable that the decis ion to unblind treatment assignment 
be discussed with the BMS Medical Monitor, but the investigator  always has ultimate aut hority 
for the decision to unblind. The Principal Investigator [INVESTIGATOR_215281] n to discontinue the subject has been made. On ce the subject is unblinded, the 
decision to discontinue cannot be reversed. For this study, the method of unblinding for emergency purposes is through the IVRS. For 
information on how to unblind for emergency, please consult the  IVRS manual.
In cases of accidental unblinding, contact [CONTACT_215322].
On 09-Dec-2020, the DMC conducted a pre-planned routine safety re view of all available safety 
data and initially recommended th at the study continue unchange d. Subsequently, the DMC noted 
that it is not possible for the study to demonstr ate an OS benefit for the investigational treatment 
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_259023]
For this study, IP (those supplied by [CONTACT_215323]) such as partially used 
study drug containers, vials and syringes may be destroyed on s ite. 
If... Then...
IP supplied by [CONTACT_20444] (including its 
vendors)Any unused IP supplied by [CONTACT_215324], or to 
meet local regulations (eg, cytotoxics or biologics).
If IP will be ret urned, the return will be arranged by [CONTACT_215325].
IP sourced by [CONTACT_3725], not supplied by [CONTACT_20444] 
(or its vendors) (examples include IP 
sourced from the sites stock or commercial 
supply, or a specialty pharmacy)It is the investigatorâ€™s or designeeâ€™s responsibility to dispos e of all 
containers according to the institutional guidelines and procedures.
It is the investigatorâ€™s or designeeâ€™s responsibility to arrang e for disposal, provided that procedures 
for proper disposal have been established according to applicab le federal, state, local, and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
The following minimal standards must be met:
â€¢On-site disposal practices must not expose humans to risks from  the drug.
â€¢On-site disposal practices and procedures are in agr eement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
â€¢Written procedures for on-site disposal are available and follo wed. The procedures must be 
filed with the siteâ€™s SOPs and a copy provided to B MS upon requ est.
â€¢Records are maintain ed that allow for traceability of each cont ainer, including the date 
disposed of, quantity disposed, and identif ication of the person disposing the containers. The 
method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal vendor 
must be documented.
â€¢Accountability and disposal records are complete, up-to-date, a nd available for the Monitor to 
review throughout the clinical trial period.
Protocol Amendment No.: 07
Date: 02-Sep-2021 60
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
It is the investigatorâ€™s or designeeâ€™s responsibility to arrange  for disposal of all empty containers.
If conditions for destruction cannot be met the responsible Stu dy Monitor will make arrangements 
for return of IP provided by [CONTACT_20444] (or its ve ndors). Destruction of non-IP sourced by [CONTACT_779], not 
supplied by [CONTACT_20444], is solely the responsibility of the investigat or or designee.
Please refer to  Section 9.2.2 for guidance on IP records and documentation. 
4.9 Retained Samples for Bioavailability/Bioequivalence
Not applicable. 
Protocol Amendment No.: 07
Date: 02-Sep-2021 61
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
5 STUDY ASSESSMENTS AND PROCEDURES
5.1 Flow Chart/Time and Events Schedule 
Table 5.1-1: Screening Procedures (CA209548)
ProcedureScreening
VisitNotes: Windows refer to calendar days
Informed Consent for enrollment X Call IVRS to obtain subject num ber
Inclusion/Exclusion Criteria X Centrally-confirmed MGMT-methylate d or indeterminate GBM
Medical History X
Physical Examination, Vital Signs, 
Performance StatusX Height, weight, BSA; Karnofsky Performance Status ( Appendix 3), and full physical exam, BP, HR, 
RR, temperature, within [ADDRESS_259024]-surgery (w ithin 24 hours preferred); see Imaging 
Manual. If not available, must be performed prior to randomizat ion (> [ADDRESS_259025]-op preferred). 
See Section 5.4 .
Assessment of Signs and Symptoms X Within 14 days prior to random ization
Concomitant Medication Collection X Within 14 days prior to rando mization, to include corticosteroid dose
Adverse Events Assessment X Serious Adverse Events from time of c onsent. See Section 6.1.1
Laboratory Tests XCBC w/differential; Chemistry panel including: AST, ALT, ALP, T .Bili, BUN or serum urea level, 
albumin, creatinine, phosphorus, Ca, Na, K, Cl, Glucose, within  14 days prior to randomization.
TSH, T3 and T4 (Free or Total), Hep B/C (HBsAG, HCV antibody or  HCV RNA), within [ADDRESS_259026] [WOCBP] XSerum or urine pregnancy test (minimum sensitivity 25 IU/L or e quivalent units of HCG ) to be done 
at screening visit and within [ADDRESS_259027]-operative baseline MRI followi ng consensus recommendations mus t be obtained prior to randomization. It is strongly recommende d that this scan be obtained 
<72 hours or >[ADDRESS_259028]. There is no requirement that MRI performed prior to randomization be on a â€œqualified machine.â€
See Section 5.4 .
Protocol Amendment No.: 07
Date: 02-Sep-2021 62
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Table 5.1-2: On-Treatment Assessments (CA209 548)a
ProcedureConcomitant 
RT + TMZ + 
Nivo/
placeboTMZ 
Break/
Nivo/
placeboMaintenanceNotes: Cycle duration is 2 weeks until 8 doses of nivo/placebo are 
complete. Remaining subsequent cycles are [ADDRESS_259029] at each visit, includ ing steroid dose
Radiation Therapy X Total dose 60 Gy over 6-7 weeks, see Section [IP_ADDRESS]
CBC with Differential X X X Weekly during RT, then Day 1 and 22 of maintenance TMZ (repeat 
weekly if TMZ delayed), then prior to each nivo/placebo dose, a nd as 
clinically indicated.
Chemistry PanelaXXXChemistry panel every 4 weeks prior to nivolumab/placebo dose: AST, 
ALT, ALP, T.Bili, albumin, BUN or serum urea, creatinine, Ca, N a, K, 
Cl, Glucose, and as clinically indicated.
Thyroid Function Test X XTSH every 8 weeks, T3 and T4 (Free or Total, if TSH abnormal) and as clinically indicated
Pregnancy Test [WOCBP only] X X XSerum or urine pregnancy test every 4 weeks ( Â±3 days; minimum 
sensitivity 25 IU/L or equivalent units of HCG)
Tumor Assessment XContrast-enhanced M RI 4 weeks ( Â±7 days) after completing RT, then 
every 8 weeks ( Â±7 days)bup to [ADDRESS_259030] 
discontinued all study treatment.
Protocol Amendment No.: 07
Date: 02-Sep-2021 63
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Table 5.1-2: On-Treatment Assessments (CA20954 8)a
ProcedureConcomitant 
RT + TMZ + 
Nivo/
placeboTMZ 
Break/
Nivo/
placeboMaintenanceNotes: Cycle duration is 2 weeks until 8 doses of nivo/placebo are 
complete. Remaining subsequent cycles are [ADDRESS_259031] be done within 72 hours prior to dosing unless 
otherwise specified.
Dispense Nivolumab/Placebo XDay 1 within 3 days of randomization up to 7 days prior to RT sta rt, then 
every 2 weeks for 8 doses, then every 4 weeks, see Section 4.5.1
Dispense Temozolomide X XTemozolomide taken daily during RT then 4 week break, then dail y x 5 
in 28-day cycles x 6 cycles, see Section 4.5.2
Tumor Sample Submission at time 
of progression or suspected progressionAt time of PD or suspected PDIf biopsy or surgical resection is performed at progression or suspected progression, a tumor sample (block or slides) should be submitt ed for 
central neuropathologic review 
aIf a subject disc ontinues nivolumab or placebo but continues TMZ, on-treatment assessments should continue. Chemistry panel will be collected ev ery 4 weeks 
prior to TMZ dosing.
bPer RANO, assessment of disease progression during study require s that MRI scan be performed >12 weeks after RT; it is therefore recommended that second 
on-treatment scan be performed at least 84 days after completio n of RT
Protocol Amendment No.: 07
Date: 02-Sep-2021 64
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Table 5.1-3: Treatment Follow-up and Survival Follow-up (CA209548 )
ProcedureTreatment 
Follow-upaSurvival 
Follow-upb Notes
Targeted Physical Examination X Weight, BP, HR, RR, temperature and Karnofsky Performance Status
Adverse Events Assessment X X Beyond [ADDRESS_259032] udy consent, or 
discontinuation from the study.
Laboratory Tests XCBC w/differential, LFTs, BUN, creatinine and TSH at [ADDRESS_259033] [WOCBP only] XSerum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of 
HCG)
Review of Concomitant Medications X
Tumor Assessment XEvery 8 weeks ( Â±7 days) for 24 months and then every 12 weeks until progression, 
required only for subjects who did not progress on study treatm ent (eg, discontinued 
for AEs). Following study unblinding, tumor assessments will not  continue for 
subjects who have discontinued study treatment. See Section 5.4 .  
Tumor Sample Submission at time of progression or suspected progressionAt time of PD or suspected 
PDIf biopsy or surgical resection is performed at the time of progression or suspected progression, a tumor biopsy sample (block or slides) should be submitted for central 
neuropathologic review; following study unblinding, this is optional.
Protocol Amendment No.: 07
Date: 02-Sep-2021 65
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Table 5.1-3: Treatment Follow-up and Survival Follow-up (CA209548 )
ProcedureTreatment 
Follow-upaSurvival 
Follow-upb Notes
Survival Status X XEvery 3 months (clinic visit or telephone cont act), during Survival phase, include 
documentation of subsequent chemotherapy. Following study unblinding, survival 
status will not be collected.
aSubjects must be fo llowed for at least [ADDRESS_259034] dose  of study drug (whichever was administered the l atest). Follow-up visit #1 (FU1) occurs
approximately 35 days ( Â±7 days) after the last dose or coinciding with the date of discontinuation ( Â±7 days) if date o f discontinuation is greater than [ADDRESS_259035] dose. Follow-up visit #2 (FU2) occurs approximately 115 days ( Â±7 days) after last dose. Following study unb linding, Follow-up Visit #1 and Follow-
up Visit #2 will occur for s ubjects who were treated wit h nivolumab, and Follow-up Visit #[ADDRESS_259036].
Protocol Amendment No.: 07
Date: 02-Sep-2021 66
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
5.1.1 Retesting During Screening or Lead-in Period
Retesting of laboratory parameters and/or other assessments wit hin the screening period will be 
permitted (in addition to any parameters that require a confirm atory value). Screening procedures 
that were performed do not need t o be repeated if they meet the  timing criteria in Table 5.1-1
(eg, within 14 days of rando mization, 28 days o f rando mizatio n). Laboratory parameters and/or 
assessments that are included in Table 5.1-1 , Screening Procedural Outline may be repeated in an 
effort to find all possible well-qualified subjects. Consultati on with the BMS Medical Monitor 
may be needed to identify whether repeat testing of any particu lar parameter is clinically relevant.
Any new result will override the previous result (ie, the most current result prior to randomization) 
and is the value by [CONTACT_109419], as it represents the subjectâ€™s most 
current, clinical state.
5.2 Study Materials
â€¢NCI CTCAE version 4.03
â€¢Nivolumab Investigator Brochure
â€¢SMPC and/or USPI [INVESTIGATOR_215282]
â€¢Pharmacy Binder
â€¢Laboratory Manuals for collection and handling of bl ood samples  
 and tissue specimens
â€¢Site manual for operation of interactive voice response system,  including 
enrollment/ra ndomization w orksheets
â€¢Manual for entry of local laboratory data
â€¢Pregnancy Surveillance Forms
â€¢Imaging Manual includes specifications for Radiology scan submi ssion
5.[ADDRESS_259037] dose of study drug. Concomitant 
medications including steroid dose within 14 days prior to firs t dose of study drug through the 
study treatment period w ill be collected (see Section 5.1 ).
Baseline local laboratory assessments should be done within [ADDRESS_259038] dose to include: 
CBC w/differential to include ANC, Chemistry panel including AST, ALT, alkaline phosphatase, 
total bilirubin, BUN or serum urea level, albumin, creatinine, phosphorus, Ca, Na, K, Cl, and 
glucose. TSH, T3 and T4 (Free or Total), and Hep B and C testin g (HBVs Ag, HCV Ab, or HCV 
Protocol Amendment No.: 07
Date: 02-Sep-2021 67
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
RNA) to be collected within 28 days prior to randomization (see  Table 5.1-1 ). Pregnancy testing 
for WOCBP (done locally) to be done at screening, within [ADDRESS_259039] r eceived any study drug. Toxicity a ssessments 
will be continuous during the tr eatment phase. During the safety follow-up phase ( Table 5.1-3 ), 
toxicity assessments should be done in person. Once subjects re ach the survival follow-up phase, 
either in person or documented telephone calls to assess the subjectâ€™s status are acceptable.On-treatment laboratory assessmen ts include CBC w/differential to include ANC, done weekly 
during RT, then Day 1 and 22 during maintenance TMZ, then prior  to each nivolumab/pl acebo 
cycle. Chemistry panel including AST, ALT, alkaline phosphatase , total bilirubin, albumin, BUN 
or serum urea, creatinine, Ca, Na, K, Cl, glucose will be perfor med every 4 weeks prior to 
nivolumab/placebo dosing or prior to TMZ dosing if the subject h as been determined to be in the 
placebo arm. TSH, T3 and T4 (Free or Total, only if TSH abnormal ) will be performed every [ADDRESS_259040] will be performed every 4 weeks. 
Adverse events and laboratory values will be graded according t o the NCI-CTCAE version 4.03.
On-study weight, Karnofsky performance status, and vital signs should be assessed every 2 weeks 
during RT followed by [INVESTIGATOR_135] 4 weeks in maintenance and at each on-study visit prior to dosing 
for nivolumab/placebo. Vital signs should also be taken as per institutional standard of care for 
subjects during and after dosing. The start and stop times of t he infusions s hould be documented. 
Physical examinations are to be performed as clinically indicat ed. If there are any new or 
worsening clinically significant changes since the last exam, re port changes on the appropriate 
non-serious or serious adverse events page.
Additional measures, including non-study required laboratory te sts, should be performed as 
clinically ind icated or to comply with local regu lations. Laboratory toxicities (eg, suspected drug 
inducted liver enzyme elevations) will be monitored during the follow-up phase v ia on si te/local 
labs until all study drug related toxicities resolve, return to baseline or are deemed irreversible.Evaluate participant immediately to rule out cardiac or pulmona ry toxicity if participant shows 
cardiac or pulmonary-related si gns (hypoxia, abnormal heart rat e or changes from baseline) or 
symptoms (eg, dyspnea, cough, chest pain, fatigue, palpi[INVESTIGATOR_814]) . Some of the previously referred 
to assessments may not be captured as data in the eCRF. They ar e intended to be used as safety 
monitoring by [CONTACT_215326]. Additional testing or ass essments may be performed as 
clinically necessary or where required by [CONTACT_215327] l regulations.
5.4 Efficacy Assessments
All subjects will undergo brain Magnetic Resonance Imaging (MRI ) at the time points specified 
in Table 5.1-[ADDRESS_259041] 
scan may be used; in this case, a MRI must be performed prior t o randomization (> [ADDRESS_259042]-op 
Protocol Amendment No.: 07
Date: 02-Sep-2021 68
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
preferred). Additional MRI scan may be obtained if clinically appropriate, eg, for radiotherapy 
planning, but are not required; in this case the last scan prio r to randomization that meets the 
diagnostic quality required in the imaging manual provided by t he central imaging vendor will be 
considered the baseline MRI. 
On treatment and follow-up assessments may be performed at desi gnated time points in Table 5.1-
2and Table 5.1-3 (Â±7 days). Per RANO, assessment of disease progression during stu dy requires 
that MRI scan be performed >12 weeks after RT; it is, therefore , recommended that second 
on-treatment scan be performed at least 84 days after completio n of RT. Investigators ma y obtain 
more frequent follow-up MRI scans as med ically ind icated. 
 
 Local radiologic assessment of tumor measurem ents will be used for clinical 
management and investigator-assessed disease progression (see Section [IP_ADDRESS] and Section 5.4.2 ).
Subjects who are unable (due to coexisting medical condition, e g, pacemaker or ICD device) or 
unwilling to have a brain MRI at baseline are excluded from the  study. Subjects who become 
unable to undergo MRI imaging after randomization may continue in the study for assessment of 
overall survival as long as there is no safety issue which woul d require monitoring by [CONTACT_9268]. 
Images will be submitted to a central imaging vendor for blinde d independent central review 
(BICR) at any time during the study until study unblinding. Prior to scanning first participant, sites 
should be qualified and understand the image acquisition guidel ines and submission process as 
outlined in the CA209-[ADDRESS_259043] 
medical/clinical judgment.
Sites will be trained in image acquisition parameters, image su bmission process, application of 
RANO criteria34(as outlined in Section 5.4.2 ) prior to scanning the first study subject. These 
guidelines will be outlined in a separate Site Imaging Manual, following recent consensus 
recommendations.51All radiologic imaging from this study (including scans performed prior to 
Screening) until study unblinding will be transmitted to a centr alized imaging core lab for BICR.
Any incidental findings of potential clinical relevance that ar e not directly associated with the 
objectives of the protocol should be evaluated and handled by t he Study investigator as per 
standard medical/clinical judgment.
5.4.1 Suspected Progression
In order to distinguish potential tr eatment eff ects (or â€œpse udoprogressionâ€) from progressive 
disease and thus to minimize premature discontinuation of nivol umab or temozolomide, subjects 
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_259044] be confirmed by 
[CONTACT_215328] 8 weeks after the initial radio logical assessment of progression. 
Prior to 12 weeks after RT, progression can only be defined using diagnostic imaging if the re is 
new enhancement outside of the  radiation field (beyond the high -dose region or 80% isodose line) 
or if there is unequivocal evidence of viable tumor on histopat hologic sampling.33Note: in the 
absence of radiographic or histologic confirmation of progressi on, clinical decline alone is not 
sufficient for definition of progressive disease. 
If the follow-up assessment confirms that progression has occur red, the date of  progression will 
be the date at which progression was first determined. If the follow-up assessment does not confirm 
progression, then the original time point response will be asse ssed as SD.
5.4.[ADDRESS_259045] no lesion measuring â‰¥[ADDRESS_259046] a complete or par tial response and will be  followed only for recurrence. These 
subjects w ill be consider ed non-evaluable for BOR analysis, but  their disease status w ill be 
assessed (SD or PD) at each tumor assessment, a nd they will be included in analysis of PFS and 
OS. If no signs of progression are observed, according to MRI, the radiologic assessment will be 
categorized as SD. The appear ance of any index or non-index les ion consistent with tumor will be 
categorized as PD.The assessments that will contribute to evaluation of PD includ e response assessments recorded 
between the date of randomization and the first to occur of the  following:
â€¢The date of objectively documented progression per RANO criteri a
â€¢The date of subse quent therapy, or
â€¢The date of pathology results from diagnostic surgical resectio n
The criteria in Table 5.4.2-1 will be used for assessi ng progression.
Protocol Amendment No.: 07
Date: 02-Sep-2021 70
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Table 5.4.2-1: Criteria for Determining First Progression Depending on Time 
From Initial Chemoradiotherapy 
Response Criteriaa
Progressive disease
< 12 weeks after
completion of
chemoradiotherapyProgression can only be defined using diag nostic imaging if there is new enhancement 
outside of the radiation field (beyond the hig h-dose region or 80% isodose line) or if there 
is unequivocal evidence of viable tumor on h istopathologic sampling (eg, solid tumor areas 
[ie, > 70% tumor cell nuclei in areas], high o r progressive increase in  MIB-1 proliferation 
index compared with prior biops y, or evidence for histologic pr ogression or increased 
anaplasia in tumor). Note: Given the difficulty of differentiat ing true progression from 
pseudoprogression, clinical decline alone, in the absence of ra diographic or histologic 
confirmation of progression, will not be sufficient for definit ion of progressive disease in 
the first 12 weeks after completion of concurrent chemoradiothe rapy.
Progressive disease
â‰¥ [ADDRESS_259047]-enhancing lesi on outside of radiation field on decreasing, stable, or 
increasing doses of corticosteroids.
2. Increase by â‰¥ 25% in the sum of the products of perpendicular diameters betwe en the 
first postradiotherapy scan, or a subsequent scan with smaller t umor size, and the scan at 
12 weeks or later on stable or increasing doses of corticosteroi ds.
3. Clinical deterioration not attributable to concurrent medication or comorbid conditions 
is sufficient to declare progression on current treatment but not for entry onto a clinical trial for recurrence.
4. For patients receiving antiangiogenic therapy, significant i ncrease in T2/FLAIR 
nonenhancing lesion may also be considered progressive disease.  The increased T2/FLAIR 
must have occurred with the patient on stable or increasing dos es of corticosteroids 
compared with baseline scan or best response after initiation o f therapy and not be a result 
of comorbid events (eg, effects  of radiation therapy, demyelina tion, ischemic injury, 
infection, seizures, postoperative changes, or other treatment effects).
NOTE: Radiologic interpretation guidelines, definitions and tumo r measurement instructions will be provided 
separately in a separate imaging manual. All measurable and nonmeasurable lesions must be assessed using the same 
techniques as at baseli ne.
Abbreviations: MRI, magnetic resonance imaging; FLAIR, fluid-attenuated inversion r ecovery
* Stable doses of corticosteroids include subjects not on corticosteroids
Table 5.4.2-2: Assessment of Best Overall Response
Best Overall Response Criteria
Complete Response (CR) CR observed in consecutive assessments â‰¥4 weeks apart per RANO
Partial Response (PR) PR observed in consecutive assessments â‰¥4 weeks apart per RANO
Stable Disease ( SD)aSD observed and does not qualify for CR or PR
orSuspected PD followed with histologic results not confirming PD, a nd no 
CR, PR or SD observed
Protocol Amendment No.: 07
Date: 02-Sep-2021 71
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Table 5.4.2-2: Assessment of Best Overall Response
Best Overall Response Criteria
Not Evaluable (NE) Insufficient data to determine disease progre ssion or response
Progressive Disease (PD) No CR, PR, or SD prior to PD
a To qualify for SD there must be a minimu m on-treatment period of [ADDRESS_259048]â€™s best  response will depend on the 
subsequent assessments. For example, a subject who has SD at a time point < [ADDRESS_259049] response of PD.
Protocol Amendment No.: 07
Date: 02-Sep-2021 72
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 73
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
5.6.1 Tumor Samples
 
Tumor tissu e (block or slides) 
must be available for submission prior to randomization. If a b lock is not available, a minimum of 
20 unstained slides of g ood qu ality is required. In situations where on-tr eatment biopsies or 
surgeries are performed, tumor sample should be sent for centra l pathology reading.
[IP_ADDRESS] Tumor Sample Collection Details
Collection of tumor tissue at diagnostic  surgery is require d for study eligibility. Additional biopsies 
obtained at any time, eg, if progression is suspected, should a lso be submitted. 
Biopsy samples from ne urosurgical resections should be fixed in 10% Neutral-buffered formalin 
for 24 â€“ 48 hours prior to paraffin embedding. Tumor tissue samp les should not be shipped in 
formalin as the temperature and length of fixation cannot be co ntrolled during shippi[INVESTIGATOR_007].
 2 paraffin blo cks are requested 
(1 minimum). If only slides are a vailable, they s hould be unstai ned, have a recommended tissue 
section thickness of [ADDRESS_259050] be shipped refrigerated at 
2-8Â° C.
An assessment of tissue quality by a pathologist is strongly en couraged at the time of the 
procedure. 
Protocol Amendment No.: 07
Date: 02-Sep-2021 74
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Sample shipments should include a completed requisition form co ntaining collection d ate, 
collection method, primary/met, site, fixation c onditions, and a copy of the pathology report, if 
available.
Detailed instructions of the obtaining, processing, labeling, h andling, storage, and shipment of 
specimens will be provided in a separate Procedure Manual at th e time of study initiation.
[IP_ADDRESS] MGMT Status
Randomization to this study is limited to sub jects with established MGMT-methylated or 
indeterminate status. Testing will be performed using a central ized RT-PCR assay through study 
CA209498.
Protocol Amendment No.: 07
Date: 02-Sep-2021 75
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 76
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 77
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
5.8 Other Assessments 
5.8.1
Results of Central Pathology Reading
In situations where on -treatment bi opsies or surgeries are performed, tumor sample should be sent 
for central pathology reading. Instructions for shippi[INVESTIGATOR_215283]/slides can be found in the 
lab manual. Investigators will receive central pathology result s.
5.8.3 Results of Central Radiology Assessments
The clinical management of subjects  during the study protocol a nd PFS will be based upon local 
radiologic tumor measurements and the investigator-assessed RAN O response criteria described 
in Section 1.2 . Radiologic imaging from this study will be also be transmitte d to a centralized 
imaging core lab until study unblinding for storage and for analysis by [CONTACT_215329]. The site will be informed of quality issues or need for  repeat scanning via queries from the 
core lab.
6 ADVERSE EVENTS
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening o f a 
preexisting medical condition in a clinical investigation subje ct administered study drug and that 
does not necessarily have a causal relationship with this treat ment. An AE can therefore be any 
unfavorable and unintended sign (s uch as an abnormal laboratory  finding), symptom , or disease 
Protocol Amendment No.: 07
Date: 02-Sep-2021 78
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
temporally associated with the use of study drug, whether or no t considered related to the study 
drug.
The definition of immune-mediated AEs can be found in Section 0 .
The causal relationship to study drug is determined by a physic ian and should be used to assess all 
adverse events (AE). The causal relationship can be one of the following:
Related: There is a reasonable causal relationship between stud y treatment administration
(including SOC) and the AE.
Not related: There is not a reasonable causal relationship betw een study treatment
administration and the AE. 
The term "reasonable causal relationship" means there is eviden ce to suggest a causal relationship. 
In this study the relationship may be assessed to any component of the study treatm ent: radiation 
therapy, TMZ, and/or nivolumab/placebo.
Adverse events can be spontaneously reported  or elicited  during open-ended questioning, 
examination, or evaluation of a subject. (In order to prevent reporting bias, subjects should not be 
questioned regarding the specific occurrence of one or more AEs.)
BMS will be reporting adverse events to regulatory authorities and ethics committees according to 
local applicable laws including European Directive 2001/20/EC a nd FDA Code of Federal 
Regulations 21 CFR Parts 312 and 320.
6.1 Serious Adverse Events
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: 
â€¢results in death
â€¢is life-threatening (defined as an event in which the subject was at risk of death at the time of 
the event; it does not refer to an event which hypothetically m ight have caused death if it were 
more severe)
â€¢requires inpatient  hospi[INVESTIGATOR_61807] s prolongation of ex isting hospi[INVESTIGATOR_059] (see NOTE
below)
â€¢results in persistent or significant disability/incapacity
â€¢is a congenital anomaly/birth defect 
â€¢is an important medical event (defined as a medical event(s) that may not be immediately life-threatening or result in death or hospi[INVESTIGATOR_313], based up on appropriate medical and 
scientific judgment, may jeopardize the subject or may require intervention [eg, medical, 
surgi cal] to prevent one of the other serious outcomes listed in the  definition above.) Examples 
of such events include, but are not limited to, intensive treatment in an emergency room  or at 
home for allergic bronchospasm; blood dyscrasias or co nvulsions that do not result in 
hospi[INVESTIGATOR_059].) Potential drug induced liver injury (DILI) is  also considered an important 
medical event. (See  Section 6.6 for the definition of potential DILI)
Protocol Amendment No.: 07
Date: 02-Sep-2021 79
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Suspected transmission of an infectious agent (eg, pathogenic o r nonpathogenic) via the study d rug 
is an SAE. 
Although pregna ncy, overdose, cancer, a nd potential drug induce d liver injury (DILI) are not 
always serious by [CONTACT_8661], these events must be h andled as SAEs. (See Section 6.1.1
for reporting pregnancies).Any component of a study endpoint that is considered related to  study therapy (eg, d eath is an 
endpoint, if death o ccurred due to anaphylaxis, anaphylaxis mus t be reported) should be reported 
as SAE. (See Section 6.1.1 for reporting details).
NOTE : 
The following hospi[INVESTIGATOR_215284]: 
âˆ’a visit to the emergency room or other hospi[INVESTIGATOR_20347] < 24  hours, that does not result 
in admission (unless considered an important medical or life-th reatening event)
âˆ’elective surgery, planned prior to signing consent
âˆ’admissions as per protocol for a planned medical/surgical procedure
âˆ’routine h ealth assessment requi ring admission for baseline/trending of h ealth status 
(eg, routine colonoscopy)
âˆ’medical/surgical admission other than to remedy ill h ealth a nd planned prior to entry into 
the study. Appropriate documentation is required in these cases
âˆ’admission encountered for another life circumstance that carrie s no bearing on health status 
and requires no medical/surgical in tervention (eg, lack of hous ing, economic inadequacy, 
caregiver respi[INVESTIGATOR_040], family circumstances, administrative reason)
âˆ’admission for administration of anticancer therapy in the absenc e of any other SAEs 
6.1.1 Serious Adverse Event Collection and Reporting
Sections 5.6.1 and 5.6.2 in the Investigator Brochure (IB) represent the Reference Safet y 
Information to determine expectedness of serious adverse events  for expedited reporting. 
Following the subjectâ€™s written consent to participate in the s tudy, all SAEs, whether related or not 
related to study drug, must be collected, including those thought to be associat ed with 
protocol-specified procedures. All SAEs, a nd all AEs (SAEs and non-serious AEs) associated with 
confirmed or suspected SARS-CoV-[ADDRESS_259051] be collected that  relate to any later protocol-
specified procedure (eg, a follow-up skin biopsy). For subjects  randomized and never treated with 
study drug, SAEs should be collected for [ADDRESS_259052] s regarding its seriousness. 
Protocol Amendment No.: 07
Date: 02-Sep-2021 80
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
If the investigator believes that an SAE is not related to stud y drug, but is potentially related to the 
conditions of the study (such as withdrawal of previous therapy  or a complication of a study 
procedure), the relationship must be specified in the narrative  section of the SAE Report Form.
SAEs, whether related or not  related to study d rug, and pregnan cies must be reported to BMS 
(or designee) within [ADDRESS_259053] be recorded on the SAE Report 
Form; pregnancies on a Pregna ncy Surveillance Form (electronic or paper forms). The preferred 
method for SAE data reporting co llection is t hrough the eCRF. The paper SAE/pregnancy 
surveillance forms are only intended as a back-up option when t he eCRF system is  not functioning. 
In this case, the paper forms are to be transmitted via email o r confirmed facsimile (fax) 
transmission to:
SAE Email Address: Refer to Contact [CONTACT_20491].
SAE Facsimile Number: Refer to Contact [CONTACT_20491].
For studies capturing SAEs through electronic data capture (EDC) , electronic submission is the 
required method for reporting. In the event the el ectronic system is unavailable for transmission, 
paper forms must be used and submitted immediately. When paper forms are used, the original 
paper forms are to remain on site.SAE Telephone Contact (required for SAE and pregnancy reporting): Refer to Contact 
[CONTACT_20491].If only limited information is  initially available, follow-up reports are required. (Note: Follow-up 
SAE reports must include the same investigator term(s) initiall y reported.) 
If an ongoing SAE changes in its intensity or relationship to s tudy drug or if n ew information 
becomes available, the SAE report must be updated and submitted  within 24 hours to BMS 
(or designee) using the same procedure used for transmitting the  initial SAE report.
All SAEs must be followed to resolution or stabilization.BMS will be reporting adverse events to regulatory authorities and ethics committees according to 
local applicable laws including European Directive 2001/20/EC a nd FDA Code of Federal 
Regulations 21 CFR Parts 312 a nd 320. A S[LOCATION_003]R  (Suspected, Unexp ected Serious Adverse 
Reaction) is a subset of SAEs and will be reported to the appro priate regulatory authorities and 
investigators following local and global guidelines and require ments. 
6.2 Nonserious Adverse Events
Anonserious adverse event is an AE not classified as serious.
6.2.1 Nonserious Adverse Event Collection and Reporting
The collection of nonserious AE information (with the exception  of non-serious AEs related to 
SARS-CoV-2 infection) should begin at initiation of study drug. Nonserious AE information 
should also be collected from the start of a placebo lead-in period or other observational period 
intended to establish a baseline status for the subjects. 
Protocol Amendment No.: 07
Date: 02-Sep-2021 81
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Nonserious AEs should be followed to resolution or stab ilization, or reported as SAEs if they 
become serious (see Section 6.1.1 ). Follow-up is also required for nonserious AEs that cause 
interruption or discontinua tion of study drug and for those present at the end of study treatment as 
appropriate. All identified nonserious AEs must be recorded and  described on the nonserious 
AE page of the CRF (paper or electronic). 
All nonserious adverse events (not only those deemed to be trea tment-related) should be collected 
continuously during the tr eatment period a nd for a minimum of  [ADDRESS_259054]â€™s case report form.
Completion of supplemental CRFs may be requested for AEs and/or laboratory abnormalities that 
are reported/identified during the course of the study.
6.[ADDRESS_259055] result abnormalities should be ca ptured on the nonserious AE CRF 
page or SAE Report Form (electronic) as appropriate: Paper forms are only intended as a back-up 
option when the electronic system is not functioning.
â€¢Any laboratory test result that is clinically significant or me ets the definition of an SAE 
â€¢Any laboratory test result abnormality that required the subjec t to have study drug discontinued 
or interrupted
â€¢Any laboratory test result abnorm ality that required the subjec t to receive specific corrective 
therapy.
It is expected that wherever possible, the clinical rather than laboratory term would be used by [CONTACT_35867] (eg, anemia versus low hemoglobin value) .
6.[ADDRESS_259056] cases, the study drug will be permanently discontinued in an appropriate manner (eg, dose 
tapering if necessary for s ubject safety).  Please call S ponsor or designee within [ADDRESS_259057] immediately notify the BMS (or designee) Medical Monit or of this event 
and complete and forward a Pre gnancy Surveillance Form to BMS ( or designee) within 24 hours 
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_259058] be re ported on the Pregnancy 
Surveillance Form.
Any pregnancy that occurs in a female partner of a male study p articipant within 6 months (or as 
noted in the lo cally applicable package insert, summary of prod uct characteristics [SmPC] or 
similar document) of the last dose of TMZ s hould be  reported to Sponsor or designee. In order for 
BMS to collect any pregnancy surveillance information from the female partner, the female partner 
must sign an informed consent form for disclosure of this infor mation. Information on this 
pregnancy will be collected on the Pregnancy Surveillance Form.
6.[ADDRESS_259059] be 
reported as an SAE (see Section 6.1.1 for reporting details).
6.6 Potential Drug Induced Liver Injury (DILI)Wherever possible, t imely confirmation of initial liver-related  laboratory abnormalities s hould 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meeting 
the defined criteria, must be reported as SAEs (see Section 6.1.1 for reporting details).
Potential drug induced liver injury is defined as: 
â€¢AT (ALT or AST) elevation > 3 times upper limit of normal (ULN)
AND
â€¢Total bilirubin > [ADDRESS_259060], without init ial findings of cholestasis ( elevated serum alkaline 
phosphatase),
AND
â€¢No other immediately apparent possible causes of AT elevation a nd hyperbilirubinemia, 
including, but not limi ted to, viral hepatitis, pre-existing ch ronic or acute liver disease, or the 
administration of ot her drug(s) known to be hepatotoxic.
6.7 Other Safety Considerations
Any significant worsening noted during interim or final physica l examinations, electrocardiogram, 
x-ray filming, any other potential safety assessment required o r not required by [CONTACT_61892] a nonserious or serious AE, as appropriate, and reported accordingly. 
Immune-mediated adverse events are AEs consistent with an immun e-mediated mechanism or 
immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor 
progression) have been ruled out. IMAEs can include events with  an alternate etiology which were 
exacerbated by [CONTACT_104155]. I nformation suppo rting the assessment will be 
collected on the subjectâ€™s case report form.
Protocol Amendment No.: 07
Date: 02-Sep-2021 83
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
â€œTreatment effect,â€ collected in C NS studies only, is a neurolo gic AE related to nivolumab 
attributable to the immune-r eaction at or around the tumor site. Most commonly, these are 
confusion, seizure, weakness, vo miting, aphasia, hydrocephalus,  etc (depending on tumor site). 
Use of â€œtumor flareâ€ as a single aggregate AE term is preferabl e to reporting each individual 
neurologic finding.  [Note: MRI findings per se are not AEs.]
7 DATA MONITORING COMMITTEE AND OTHER EXTERNAL 
COMMITTEES
When required, adjudicated events will be submitted to the DMC and Health Authori ties for review 
on a specified timeframe in accordance with the adjudication do cumentation.
A Data Monitoring Committee w ill be established to  provide oversight of safety and eff icacy 
evaluation of the entire study and to provide advice to the sponsor regarding actions the committee 
deems necessary for the continuing protection of subjects. The DMC will be charged with 
assessing such actions in light of an acceptable benefit/risk p rofile for nivolumab. The DMC will 
act in an advisory capacity to BMS and w ill monitor s ubject safety and evaluate the available 
efficacy data for the study. The oncology therapeutic area of B MS has primary responsibility for 
design and conduct of the study. The DMC will meet at least eve ry 6 months or more frequently 
as needed on an ad-hoc basis. Information regarding DMC members hip, responsibilities, and 
procedures are detailed in the DMC charter. The DMC will be inf ormed should a safety signal 
emerge and may convene an ad-hoc meeting on its own initiative. The DMC will review all 
available data (safety and efficacy) at each meeting. At the co nclusion of each DMC meeting the 
committee, will provide the sponsor with a recommendation to co ntinue, modify or terminate the 
study protocol base d upon their review. Ultimately, decisions r egarding the study protocol will be 
made by [CONTACT_215330]. Following study unblinding, the DMC will be discontinued, and the s ponsor w ill monitor safety for the 
subjects remaining on treatment.
8 STATISTICAL CONSIDERATIONS
8.1 Sample Size Determination
This is a Phase 3, randomized, single blinded, multicenter stud y of RT + TMZ + nivolumab or 
placebo in adult ( â‰¥18 years) subjects with newly diagnosed GBM and MGMT-methylated  or 
indeterminate tumors.
The familywise type I error rate for the primary comparisons wi ll be set to 0.05, with 0.01 being 
allocated to the PFS comparison and 0.04 being allocated to the  OS comparison. 
The primary objectives of the study are:
â€¢to compare progression-free survival (PFS) in an all-comers gro up of subjects with newly 
diagnosed MGMT-methylated or indeterminate GBM subtypes treated  with RT plus TMZ 
combined with ni volumab or placebo.
â€¢to compare overall survival (OS) of subjects with newly diagnos ed MGMT methylated or 
indeterminate GBM subtypes without baseline corticosteroids and  regardless of baseline 
Protocol Amendment No.: 07
Date: 02-Sep-2021 84
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
corticosteroids (ie, all-comers) treated with RT plus TMZ combi ned with nivolumab or
placebo. 
These primary objectives on OS will test RT plus TMZ combined wit h nivolumab or placebo in 
the following hierarchy via a stratified log rank test: 
1) OS in newly diagnosed MGMT-methylated or indeterminate GBM su btype without baseline 
corticosteroids. 
2) If 1 is significant, OS in newly-diagnosed MGMT-methylated or  indeterminate GBM subtype 
regardless of baseline steroid use (all comers).
The sample size for this study is based on the following assump tions:
â€¢PFS and OS follows exponential distribution
â€¢Median PFS in RT+TMZ arm is 10 .0 months
â€¢Hazard ratio (HR) of arm RT + TMZ + nivolumab vs RT + TMZ for PFS is 0 .68, translated to 
median PFS improvement of 4.7 months (10.0 months vs 14.7 months  for arm RT + TMZ and 
arm RT + TMZ + nivolumab, respectively)
â€¢Median OS in RT+TMZ arm is 26.0 months54
â€¢Hazard ratio (HR) of arm RT + TMZ + nivolumab vs RT + TMZ is 0.7 for t he randomized 
population with no baseline corticosteroi d, translated to media n OS improvement of 11.1 
months (26.0 months vs 37.1 months for arm RT + TMZ and arm RT + TM Z + nivolumab, 
respectively)
â€¢Hazard ratio (HR) of arm RT + TMZ + nivolumab vs RT + TMZ is 0.75 for  the overall 
randomized population, t ranslated to median OS improvement of 8 .7 months (26.0 months vs 
34.7 months for arm RT + TMZ and arm RT + TMZ + nivolumab, respectivel y)
â€¢Proporti on of no baseline corticosteroid population within the entire newly-diagnosed MGMT-
methylated or indeterminate GBM subtypes is 0.70
Approximately 693 subjects w ill be ra ndomized in a 1:1 ratio, str atified by [CONTACT_215331]. Of these 693 subjects, 485 subjects are assumed to be  no baseline corticosteroids. 
Accrual is estimated to take approximately 25 months based on an  observed monthly accrual in 
CA209548 of approximately 28 subjects per month; in the no base line corticosteroids population, 
a pi[INVESTIGATOR_215285] 1, 4, 5, 8, 13, 16, 19, and then [ADDRESS_259061] 337 OS events (deaths) in the no baseline corticosteroid p opulation are needed to achieve 
88% power using a 2-sided Type 1 error of 4%. This number of ev ents is projected to occur after 
an additional 44 months of follow- up (ie, at 69 months). 
One interim analysis will be condu cted on OS in the  randomized pop ulation with no baseline 
corticosteroid. It will occur approximately 20 months after accru al is finished or when 70% or 236
OS events is reached which is estimated to occur at 45 months af ter study start, providing a 58% 
probability of stoppi[INVESTIGATOR_130017] H1. The st oppi[INVESTIGATOR_215286].: 07
Date: 02-Sep-2021 85
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
be based on the actual number of OS events at the time of the a nalysis using Lan-DeMets alpha 
spending function with Oâ€™Brien-Fleming boundaries. If the plann ed interim analyses occur exactly 
at the planned number of events, the projected alpha level will  be 0.011 and 0.037. 
See Table 8.1-1 . The interim analysis will also be conducted on OS in the overa ll randomized 
population. The interim analysis w ill be conduc ted at the same time as the interim for the no 
baseline corticosteroids populat ion in a hierarchy with stoppin g boundaries at the interim and final 
analysis based on actual number of OS events at the time of the  analysis using Lan-DeMets alpha 
spending function with Oâ€™Brien-Flemi ng boundaries. 
The PFS comparisons will be based on first [ADDRESS_259062] 
404 PFS events are needed to achieve 90% power using a 2-sided T ype 1 error of 1%. Accrual is 
estimated to take approximately 23 months and this number of ev ents is proj ected to occur after 
an additional 12 months of follow-up (ie, at 35 months).
The technique of alpha-recycling will be used to adjust for mul tiplicity with details provided in 
the SAP.Power calculations were done using East v 6.3 and R.
Table 8.1-1: Key Parameters of Sample Size Calculation of PFS an d OS
Primary Endpoint PFS OS OS
Power 90% 88% 87%
Alpha 0.01 0.04 0.04
Hypothesized Median Control vs. exp (months) [ADDRESS_259063] ratio 0.68 0.7 0.75
Expected number of events for comparison 
towards primary objective404 337 494
Accrual Duration (months) 23 25 25
Sample size558 
(all-comers)485 (no baseline 
corticosteroids)693 
(all-comers)
Expected number of events at IA N/A 236 346
FPFV to IA (months) N/A 45 45
FPFV to LPLV (months) 35 69 69
8.2 Populations for Analyses
â€¢All Enrolled subjects: All subjects who signed an informed cons ent form and were registered 
into the IVRS
â€¢All Randomized sub jects: All enrolled subjects who were randomi zed to any treatment arm. 
This is the primary dataset for analyses of efficacy parameters  and baseline characteristics
â€¢All Treated subjects: All randomized subjects who received at l east one dose of study drug. 
This is the primary dataset for safety and exposure analyses.
Protocol Amendment No.: 07
Date: 02-Sep-2021 86
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
8.3 Endpoints
8.3.1 Primary Endpoint(s)
The two primary endpoints of the trial will be OS in the randomiz ed population with no 
corticosteroids at baseline as well as in the overall randomize d population, and PFS determined by 
[CONTACT_19377], based on RANO criteria (see Section 5.4.2 ).
8.3.2 Secondary Endpoint(s)
OS rate at 12 months and 24 months estimated from OS Kaplan-Meier curve.
PFS determined by [CONTACT_215303].
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_259064] tum or assessment date prior to initiation 
of surgical resection. PFS will be determined by [CONTACT_215302]. 
[IP_ADDRESS] Analyses of Primary Endpoint
The distribution of OS in the sub- populatio n of subjects with no baseline corticosteroids and in all 
randomized subjects will be compared in arms RT + TMZ + nivolumab a nd RT + TMZ at interim 
and final analyses via two-sided, log-rank tests, stratified by  [CONTACT_215332]. The boundaries for declaring superiority at the interim and final analyses will be based 
on the actual number of OS event s at the time of the analysis u sing Lan-DeMets alpha spending 
function with Oâ€™Brien-Fleming boundaries. For example, if the i nterim and final analyses occur 
exactly at the planned number of events, superiority of an arm will be declared if P â‰¤0.011 at the 
interim analysis or P â‰¤0.[ADDRESS_259065] limit meth od will be 
used to estimate the survival curve in each arm including media ns and its 95% CI, OS rates at 
various time points. The HR and the corresponding two-sided (1- adjusted Î±) % CIs will be 
estimated in a  Cox proportional hazards model with tr eatment arm as a single covariate stratified 
by [CONTACT_215306] (complete or partial surgical resection at baseline).
The comparison of PFS (by [CONTACT_19377]) will be based on a two-sided lo g-rank test stratified by 
[CONTACT_215333] (complete surgical or parti al resection at baseline). PFS will be 
compared in the first 558 subjects out of the (total) [ADDRESS_259066] 
limit method w ill be used to estimate th e survival curve in eac h arm including medians and its 
95% CI, PFS rates at vari
ous time points. The HR and the corresponding two-sided 99% CIs will 
Protocol Amendment No.: 07
Date: 02-Sep-2021 88
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
be estimated in a Cox proportional hazards model with treatment arm as a single covariate stratified 
by [CONTACT_215306] (complete or partial surgical resection at baseline).
PFS (based on BICR) will be analyzed in overall randomized subjects and all randomized subjects 
without baseline corticosteroids.
The CA209548 DMC c onvened on 09-Dec-[ADDRESS_259067] a pre-plann ed, routine safety review 
of all data. A lthough the init ial reco mmendation was that the study should continue unchanged 
and this was communicated to study investigators, subsequently the DMC notified BMS that they 
had deliberated further and unanimously agreed on the following :
â€¢The OS data clearly shows that there is no plausible scenario f or this study to have a positive 
OS result at the final analysis based on either all ra ndomized patients or on patients without 
baseline corticosteroids. This statement is based on the DMC Íƒs review of the OS results to 
date, with over 80% of the final required number of events reac hed and related statistical 
considerations including conditional power of < 1% for a statis tically significant final result.
â€¢While the group receiving nivolumab has a higher incidence of toxicities, the DMC members 
believed the increased toxicity was expected and did not warran t stoppi[INVESTIGATOR_215287] b ecause 
of safety.
The DMC recommended to unblind the sites and subjects, which wa s approved by [CONTACT_20444]. The study 
was unblinded to investigators on 22-Dec-2020. As a consequence, the timing of the primary OS 
analysis, originally planned for when 337 and 494 events were t o be reached respectively for the 
population without cor ticosteroids at bas eline and th e overall population, has be en updated. To 
prevent any bias due to unblinding of subjects, the primary OS analysis will be conducted using 
the cut-off date (or LPLV) of 22-Dec-2020, which is when the study  was unblinded.
The primary OS analysis in all rando mized sub jects without baseline corticosteroids and the 
primary PFS analysis in all randomized subjects will report a p -value as planned in the alpha 
recycling plan. Overall survival in all randomized subjects wil l be tabulated descriptively, as 
described in the current SAP. Potential subsets analyses will b e presented descriptively. The 
primary analysis of PFS per BICR will be conducted using the cu t-off date of 14-Jun-2019 with a 
database lock date of 09-Aug-2019 (the primary PFS analysis ass essed by [CONTACT_215334] 2019). The 
same analysis will also be conducted using the cut-off date of 22-Dec-2020.
Based on CP calculation (< 1%) for OS, there is no plausible sce nario for this study to have a 
positive OS result. Therefore, only selected analyses will be inc luded in the primary Clinical St udy 
Report, as described in the current SAP.
[IP_ADDRESS] Analyses of Secondary Endpoints
Overall survival rates at [ADDRESS_259068] 558 subjects, all rando mized 
subjects and all randomized subjects who did not receive corticosteroids at baseline.
Protocol Amendment No.: 07
Date: 02-Sep-2021 89
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
All secondary e ndpoints will be analyzed at the same time as the OS and PFS primary analyses
using the analysis methods already defined in the SAP.
Protocol Amendment No.: 07
Date: 02-Sep-2021 90
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
8.5 Interim Analyses
This study
 will include 1 formal interim analysis on OS for supe riority. 
A formal interim analysis for superiority of OS will be perform ed when approximately 236 (70% 
of planned events  or 236/337) events is reached in the population of no bas eline corticosteroids. 
Lan-DeMets alpha spending function with Oâ€™Brien and F leming type of boundary will be used. 
The stoppi[INVESTIGATOR_215288]. At the time of the interim  analyses, the DMC will review OS and other efficacy endpoints 
as defined in the DMC charter.
In addition to the formal planned interim analysis for OS, the DMC will have access t o periodic 
interim reports of effi cacy and safety to allow a risk/benefit assessment. Details wil l be included 
in the DMC charter. 
8.[ADDRESS_259069] udy unblinding will be followed 
per protocol through treatment discontinuation and safety follo w-up. 
The end of study analyses will be performed for the selected sa fety and durati on of treatment data
using all randomized subjects. 
Data to be reported:
â€¢Subject disposition
â€¢Duration of treatment (nivolumab, temozolomide)
â€¢Death
Protocol Amendment No.: 07
Date: 02-Sep-2021 91
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
â€¢Adverse events
â€¢Serious adverse events
9 STUDY MANAGEMENT
9.1 Compliance9.1.1 Compliance with the Protocol and Protocol Revisions
The investigator should not imp lement any deviation or change t o the protocol without prior 
review and documented approval/favorable opi[INVESTIGATOR_82703] t from the IRB/IEC (and if 
applicable, also by [CONTACT_14306]) except where necess ary to eliminate an immediate 
hazard(s) to st udy subj ects. If a dev iation or change to a protocol is implemented to eliminate an 
immediate hazard(s) prior to obtaining relevant approval/favora ble opi[INVESTIGATOR_1649](s), the deviation or 
change will be submitted as soon as possible to:
â€¢IRB/IEC
â€¢Regulatory Authority(ies), if applicable by [CONTACT_427] p er national requirements
Documentation of approval/favorable opi[INVESTIGATOR_82704](s)/IEC(s) if applicable, also by [CONTACT_14306], must be sent to BMS. If an amendment 
substantially alters the st udy design or increases the potential risk to the sub ject: (1) the consent 
form must be revised and submitted to the IRB(s)/IEC(s) for rev iew and approval/favorable 
opi[INVESTIGATOR_1649]; (2) the revised form must be used to obtain consent fr om subjects currently enrolled in 
the study if they are affected by [CONTACT_29991]; and (3) the ne w form must be used to obtain 
consent from new subjects prior to enrollment.
If the revision is done via an administrative letter, investiga tors must inform their IRB(s)/IEC(s).
9.1.[ADDRESS_259070] of the study with th e investigator, and verify that the 
facilities remain acceptable. Certain CRF pages and/or electron ic files may serve as the source 
documents.
In addition, the study may be evaluated by [CONTACT_122410], source documents , other study files, and study 
facilities. BMS audit reports will be kept confidential.
The investigator must notify BMS promptly of a ny inspections scheduled by [CONTACT_21755], 
and promptly forward copi[INVESTIGATOR_215289]. 
Protocol Amendment No.: 07
Date: 02-Sep-2021 92
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
[IP_ADDRESS] Source Documentation
The Investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attr ibutable, whether the data are hand-written on paper or entered 
electronically. If source data are created (first entered), mod ified, maintained, archived, retrieved, 
or transmitted electronically via computer ized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such s ystems must be compliant with all 
applicable laws and regulations governing use of electronic rec ords and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), 
adverse event tracking/reporting, protocol required assessments , and/or drug accountability 
records).
When paper records from such systems are used in place of electronic format to perform regulated 
activities, such paper records should be certified copi[INVESTIGATOR_014]. A ce rtified copy consists of a copy of 
original information that has been verified, as indicated by a dated signature, as an exact copy 
having all of the same attributes a nd information as the original. 
9.2 Records
9.2.1 Records Retention
The investigator (or head of study site in Japa n) must retain all study rec ords and source documents 
for the maximum period required by [CONTACT_64122] g uidelines, or institution 
procedures, or for the period specified by [CONTACT_54029], whichever is longer. The investigator 
(or head of study site in Japan) must contact [CONTACT_54029] p rior to destroying any records 
associated with the study.
BMS or designee will notify the investigator (or head of the st udy site in Japan) when the study 
records are no longer needed.If the investigator withdraws from the study (eg, relocation, r etirement), the records sh all be 
transferred to a mutually agreed upon designee (eg, another inv estigator, study site, IRB). Notice 
of such transfer will be given in writing to BMS or designee.
9.2.2 Study Drug Records 
Records for IP (whether s upplied by [CONTACT_20444], its vendors, or the site) must substantiate IP integrity 
and traceability from r eceipt, prepar ation, administration, and  through destruction or return. 
Records must be made available for review at the request of BMS/designee or a Health Authority.
If... Then...
Supplied by [CONTACT_20444] (or 
its vendors):Records or logs must comply with applicable regulations and gui delines and should 
include:
â€¢amount received and placed in storage area
â€¢amount currently in storage area
â€¢label identification number or batch number
â€¢amount dispensed to and returned by [CONTACT_6992], including unique subject 
identifiers
Protocol Amendment No.: 07
Date: 02-Sep-2021 93
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
If... Then...
â€¢amount transferred to another area/site for dispensing or storage
â€¢nonstudy disposition (eg, lost, wasted) 
â€¢amount destroyed at study site, if applicable
â€¢amount returned to BMS
â€¢retain samples for bioavailability/bioequivalence, if applicabl e 
â€¢dates and initials of person responsible for Investigational Product 
dispensing/accountability, as per the Delegation of Authority Form.
Sourced by [CONTACT_3725], and 
not supplied by [CONTACT_35885] 
(examples include IP 
sourced from the sites 
stock or commercial 
supply, or a specialty 
pharmacy)The investigator or designee accepts responsibility for documen ting traceability and 
study drug integrity in accordance with requirements applicable under law and the 
SOPs/standards of the sourcing pharmacy.   
These records should include:
â€¢label identification number or batch number 
â€¢amount dispensed to and returned by [CONTACT_6992], including unique subject 
identifiers
â€¢dates and initials of person responsible for Investigational Pr oduct 
dispensing/accountability, as per the Delegation of Authority Form.
BMS or designee will provide forms to facilitate inventory cont rol if the investigational site does 
not have an established system that meets these requirements.
9.2.[ADDRESS_259071] be 
explained.  
 CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
For sites using the Sponsor or designee electronic data capture  tool, electronic CRFs w ill be 
prepared for all data collection fields except for fields speci fic to SAEs and pregnancy, which will 
be reported on the electronic SAE form and Pregnancy Surveillan ce form, respectively. If 
electronic SAE form is not av ailable, a paper SAE form can be used. Spaces may be left blank  
only in those circumstances permitted by [CONTACT_3449]-specific CRF com pletion guidelin es provi ded by 
[CONTACT_122412]. 
The confidentiality of records that could identify subjects mus t be protected, respecting the privacy 
and confidentiality rules in accordance with the applicable reg ulatory requirement(s).
The investigator will maintain a signature [CONTACT_35899]/or corrections on CRFs. The completed CRF, SAE/pregnancy CRFs, must be promptly reviewe d, signed, and dated by [CONTACT_54025] a subinvestigator an d who is delegated this task on the 
Protocol Amendment No.: 07
Date: 02-Sep-2021 94
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Delegation of Authority Form. Subinvestigators in Japan ma y not be delegated the CRF approval 
task. For electronic CRFs, review and approval/signature [CONTACT_215342]. The investigator must retain a copy of the CRFs including 
records of the changes and corrections.
Each individual electronically si gning electronic CRFs must mee t Sponsor or designee training 
requirements and must only access the BMS electronic data captu re tool using the unique user 
account provided by [CONTACT_35886]. User accounts are not to be shared or reassigned to other 
individuals.9.[ADDRESS_259072] be selected to sign the clinical study report. 
For this protocol, the Signatory Investigator will be selected as appropriate based on the following 
criteria:
â€¢External Principal Investigator [INVESTIGATOR_122349]
â€¢National Coordinating Investigator 
â€¢Subject recruitment (eg, am ong the top quartile of enrollers)
â€¢Involvement in trial design
â€¢Regional representation (eg, amo ng top quar tile of enrollers from a specified region or country)
The data collected during this s tudy are confidential and proprietary to BMS or designee. Any 
publications or abstracts arising from this study must adhere to the publication requirements set 
forth in the clinical trial agreement (CTA) governing [Study sit e or Investigator] par ticipation in 
the study. These requirements include, but are not limited to, submitting proposed publications to 
BMS or designee at the earliest practicable time prior to submi ssion or presentation and otherwise 
within the time period set forth in the CTA.
Protocol Amendment No.: 07
Date: 02-Sep-2021 95
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
10 GLOSSARY OF TERMS
Term Definition
Complete 
AbstinenceComplete Abstinence is defined as complete avoidance of heterosexual intercourse and is an 
acceptable form of contraception for all study drugs. This also means that abstinence is the 
preferred and usual lifestyle of the patient. This does not mean  periodic abstinence (e.g., 
calendar, ovulation, symptothermal, profession of abstinence for entry into a clinical trial, 
post-ovulation methods) and withdrawal, which are not acceptable methods of contraception. Women must continue to have pregnancy tests. Acc eptable alternate methods 
of highly or less effective contraceptionâ€™s must be discussed i n the event that the subject 
chooses to forego complete abstinence.
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_259073] OF ABBREVIATIONS
Term Definition
ACTH adrenocorticotropic hormone
AE(s) adverse event(s)
AIDS Acquired Immunodeficiency Syndrome
ALT alanine aminotransferase
ALP alkaline phosphatase
ANC absolute neutrophil count
AST aspartate aminotransferase
Î²-HCG beta-human chorionic gonadotrophin
BA/BE bioavailability/bioequivalence
BICR Blinded Independent Central Review
BMS Bristol-Myers Squibb Company
BOR Best Overall Response
BP blood pressure
BSA body surface area
BUN blood urea nitrogen
Ca++ calcium
CBC complete  blood count
CFR Code of Federal Regulations 
CI confidence interval
CNS central nervous system
CR complete response
CrCl creatinine clearance
CRF Case Report Form, paper or electronic
CTA clinical trial agreement
CTCAE Common Terminology Criteria for Adverse Events
%CV% geometric mean
Protocol Amendment No.: 07
Date: 02-Sep-2021 97
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Term Definition
DILI drug-induced liver injury
dL deciliter
DMC Data Monitoring Committee
DNA deoxyribonucleic acid
DTIC Dacarbazine
EC ethics committee
ECG electrocardiogram
eCRF electronic case report form
EDC electronic data capture
Eg exempli gratia (for example)
eGFR estimated glomerular filtration rate
EGFR epi[INVESTIGATOR_215290]-attenuated inversion recovery
FSH follicle stimulating hormone
GBM glioblastoma
GCP Good Clinical Practice
Gy Gray (radiotherapy dose)
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_259074] (that is)
IEC Independent Ethics Committee
IMP investigational medicinal products
imAEs immune-mediated adverse events
IND Investigational New Drug Exemption
I-O immuno-oncology
IP investigational product
IRB Institutional Review Board
IRC Independent Radiology Review Committee
IU international unit
IUDs intrauterine devices
IV intravenous
IVRS interactive voice response system
Protocol Amendment No.: 07
Date: 02-Sep-2021 99
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Term Definition
K+ potassium
Kg kilogram
LPLV Last patient last visit
mg milligram
Mg/kg milligram per kilogram
Mg++ magnesium
MGMT tumor O-6-methylguanine  DNA methyltransferase
mL milliliter
MMR measles, mumps, rubella 
MRI magnetic resonance imaging
Î¼g microgram
N number of subjects or observations
N nivolumab (BMS-936558)
Na+ sodium
N/A not applicable
NCI National Cancer Institute
NE not evaluable
NIMP non-investigational medicinal products 
O2 oxygen
OS overall survival
Protocol Amendment No.: 07
Date: 02-Sep-2021 100
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Term Definition
PCR polymerase chain reaction
PD progressive disease
PFS progression-free survival
PID patient identifier 
PO per os (by [CONTACT_20511])
PR partial response
PVC polyvinyl chloride
QD once a day 
QOL quality of life
RANO Radiologic Assessment in Neuro-Oncology
RR respi[INVESTIGATOR_215291]-PCR reverse transcription polymerase
SAE(s) serious adverse event(s)
SARS-CoV-[ADDRESS_259075] characteristics
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_259076] operating procedures
T1/[ADDRESS_259077] upper limit of normal
w week
WBC white blood cell
WHO World Health Organization
WOCBP women of childbearing potential
Protocol Amendment No.: 07
Date: 02-Sep-2021 102
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 103
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 104
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-2021 105
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_259078] medical practice. N on-inflammatory etiologies s hould be consider ed and appropriately 
treated.
Corticosteroids are a pr imary therapy for immuno-oncology drug-related adverse events. The 
oral equivalent of the recommended IV doses may be considered f or ambulatory patients with 
low-grade toxicity. The lower bioavailability of  oral corticosteroids should be taken into account 
when switching to the equivalent dose of oral corticosteroids.Consultation with a medical or surgical specialis t, especially prior to an invasive diagnostic or 
therapeutic procedure, is recommended.The frequency and severity of the related adverse events covered by [CONTACT_20520]-oncology agent or regimen being used.
Protocol Amendment No.: 07
Date: 02-Sep-2021 107
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
28-Sep-2020
Protocol Amendment No.: 07
Date: 02-Sep-2021 108
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
28-
Sep-2020
Protocol Amendment No.: 07
Date: 02-Sep-2021 109
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
28-Sep-2020
Protocol Amendment No.: 07
Date: 02-Sep-2021 110
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
28-Sep-2020
Protocol Amendment No.: 07
Date: 02-Sep-2021 111
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
28-Sep-2020
Protocol Amendment No.: 07
Date: 02-Sep-2021 112
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
28-Sep-2020
Protocol Amendment No.: 07
Date: 02-Sep-2021 113
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
28-Sep-2020
Protocol Amendment No.: 07
Date: 02-Sep-2021 114
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
28-Sep-2020
Protocol Amendment No.: 07
Date: 02-Sep-2021 115
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
APPENDIX 2 RADIATION THERAPY GUIDELINES
Radiation therapy for GBM contri butes importantly to both effic acy and toxicity. Modern 
radiotherapeutic management of GBM was recently summarized: Niyazi  M, et al. (2016) 
ESTRO-ACROP guideline â€œtarget delineation of glioblastomasâ€. Radiother Oncol 118:35-42.
A high level of experience is assumed in participating centers.  Guidelines are provided in order 
to support appropriate homogeneity in a trial environment witho ut imposing excessive 
constraints on expert practice. Therefore, the following guideli nes should be interpreted as 
expectations rather than protocol requirements.
Dose Specification 
A total dose of 60 Gy, in 2 Gy daily fractions on 5 days/week, will be administered in 6 weeks 
(30 fractions). Radiation treatment duration may be extended du e to delays or holidays up to 
7 weeks (49 calendar days). 
Radiation treatm ent will be delivered with a megavoltage machine w ith photon energy â‰¥6 MV
utilizing either 3-D Conformal or Intensity-Modulated (IMRT or VM AT) approaches. Electron, 
particle, or implant boost is not permitted.
An initial target volume (see below definitions) will be irradia ted to [ADDRESS_259079] (supi[INVESTIGATOR_215292], eg, thermoplastic 
mask) is standard. Fusion with MR images for target and OAR del ineation is mandatory. 
Target volumes will be based upon post-operative contrast-enhanc ed MRI, although 
pre-operative imaging should be used for c orrelation, and may be modified based on subsequent 
scans if anatomic shift is evident. The method of dose volume p lanning and documentation 
should be not be investigational.
The initial gross tumor volume (GTV1) is defined by [CONTACT_28261] T2 or the FLAIR abnormality, 
including enhancing tumor volume and surgical cavity. The boost  volume (GTV2) will be based 
on the T1-enhancing tumor volume plus the surgi cal cavity. Derived clinical target volumes 
(CTV1-2) are the corresponding GTV plus a margin of approximatel y 2 cm; smaller margins are 
permitted, based on clinical judgment and anatomic constraints.  Planning target volume 
(PTV1-2) margins, ty pi[INVESTIGATOR_897] a pproximately 0.[ADDRESS_259080] 95% of the planned CT V shall receive 100% of the 
prescribed dose, with acceptable variance of 90% PTV coverage fo r clinical or technical reasons.
Isodose distributions must be recorded. Details of field modific ation will be determined by [CONTACT_215335]-accepted practice based on  primary tumor extension, natural 
structures and organs at risk (eg, optic chiasm or brainstem), as well as on re producibility 
considerations, potential overlap regions and the like.
Protocol Amendment No.: 07
Date: 02-Sep-2021 116
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
APPENDIX 3 KARNOFSKY PERFORMANCE SCALES
100 Normal; no complaints; no evidence of disease
90 Able to carry on normal activit y; minor signs or symptoms of disease
80 Normal activity with effort, s ome sign or symptoms of disease
70 Cares for self; unable to ca rry on normal  activity or do active work
[ADDRESS_259081] pe rsonal needs
50 Requires considerable assistance and frequent medical care
40 Disabled; requires special care and assistance
30 Severely disabled; hospi [INVESTIGATOR_215293], although death nor imminent
20 Very sick; hospi[INVESTIGATOR_215294]; active support treatment is necessary
10 Moribund; fatal processes progressing rapi[INVESTIGATOR_375]
0 Dead
Protocol Amendment No.: 07
Date: 02-Sep-[ADDRESS_259082] agree to use one highly effective m ethod of contraception as listed 
below. Local laws and regulations may require use of alternativ e and/or additional contraception 
methods.
HIGHLY EFFECTIVE METHODS OF CONTRACEPTION
Highly effective methods of contraception have a failure rate o f < 1% when used consistently 
and correctly. WOCBP and female partners of male subjects, who are WOCBP, are expected to 
use one of the highly effective methods of contraception listed  below. Male subjects must inform 
their female partners who are WOCBP of the contraceptive requir ements of the protocol and are 
expected to adhere to using contraception with their partner. C ontraception methods are as 
follows:1) Progestogen only hormonal contraception associated with inhib ition of ovulation.
2) Hormonal methods of contraception including oral contraceptiv e pi[INVESTIGATOR_122351] + progesterone, vaginal ring, injectables, implants an d intrauterine devices (IUDs) 
such as Mirena Â®
3) Nonhormonal IUDs, such as ParaGard Â®
4) Bilateral tubal occlusion
5) Vasectomised partner with documented azoospermia 90 days afte r procedure
â™¦Vasectomised partner is a highly effective birth control method  provided that partner is 
the sole sexual partner of the WOCBP trial participant and that  the vasectomised partner 
has received medical assessment of the surgical success.
6) Intrauterine hormone-releasing system (IUS).7) Complete abstinence
â™¦Complete abstinence is defined as the complete avoidance of het erosexual intercourse 
(refer to Glossary of Terms)
â™¦Complete abstinence is an acceptable form of contraception for all study d rugs and must 
be used throughout the duration of the study treatment (plus 5 half-lives of the 
investigational drug plus 30 days).
â™¦It is not necessary to use any other method of contraception wh en complete abstinence is 
elected.
â™¦Subjects who choose complete abstinence must continue to have p regnancy tests, as 
specified in Section 5.
â™¦Acceptable alternate methods of highly effective contraception must be discussed in the 
event that the subject chooses to forego complete abstinence.
â™¦The reliability of sexual abstinence needs to be evaluated in r elation to the duration of the 
clinical trial and the preferred and usual lifestyle of the sub ject.
Protocol Amendment No.: 07
Date: 02-Sep-2021 118
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
UNACCEPTABLE METHODS OF CONTRACEPTION
1) Periodic abstinence (calendar, symptothermal, post-ovulation methods)
2) Withdrawal (coitus interruptus)
3) Spermicide only4) Lactation amenorrhea method (LAM)
Protocol Amendment No.: 07
Date: 02-Sep-2021 119
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
APPENDIX 5 PROTOCOL AMENDMENT SUMMARY OF CHANGE HISTORY
Overall Rationale for Protocol Amendment 06, 26-Feb-2021
The CA209548 Data Monitoring Committee (DMC) convened on 09-Dec -[ADDRESS_259083] udy investigators, 
subsequently the DMC notified BMS that they had deliberated further and unanimously agreed 
on the following:
â€¢The overall survival (OS) data clearly shows that there is no plausible scenario for this stud y 
to have a positive OS result at the final analysis based on eit her all randomized patients or on 
patients without baseline corticosteroids. This statement is ba sed on the DMCâ€™s review of the 
OS results to date, with over 80% of the final required number of events reached and related 
statistical considerations including conditional power of < 1% for a stati stically si gnificant 
final result.
â€¢While the group receiving nivolumab has a higher incidence of toxicities, the DMC members 
believed the increased toxicity was expected and did not warran t stoppi[INVESTIGATOR_215287] b ecause 
of safety.
The DMC recommended to unblind the sites and patients, which wa s approved by [CONTACT_20444]. The 
study was unblinded to investigators on 22-Dec-2020. As a conse quence, the timing of the 
primary OS analysis, originally planned for when 337 and 494 ev ents were to be reached 
respectively f or the populati on without corticosteroids at baseline and the overall populati on, has 
been updated. To prevent any bias due to unblinding of patients , the primary OS analysis will be 
conducted using th e cut-off date (or last patient last visit [LPLV]) of 22-Dec-2020, which is 
when the study was unblinded.
Following unblinding, study subjects who were currently on nivol umab therapy, tolerating the 
treatment, and were considere d by [CONTACT_215336]. However, study procedures in the treat ment and follow-up phases are 
now simplified, since additiona l post-unblindi ng data are no longer needed for analyses.
Protocol languages per BMS standards for nivolumab studies and for COVID-[ADDRESS_259084] also been 
incorporated. 
This protocol amendment incorporates the changes from the a pproved Administrative Letters 10 
and 11 which are not detailed in the summary of key changes bel ow.
Summary of key changes of Protocol Amendment 06
Section Number & Title Description of Change Brief Rationale
Title PageThe study contacts and naming 
conventions have been updated.
The name, address, and 
confidentiality statement of the 
Sponsor have been updated. Changes in BMS personnel and team 
assignments.
Changes in the BMS protocol model 
document.
Protocol Amendment No.: 07
Date: 02-Sep-2021 120
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Summary of key changes of Protocol Amendment 06
Section Number & Title Description of Change Brief Rationale
Summary: Study DesignUnblinding information has been 
added.
Follow-up for progression and 
survival after study treatment 
discontinuation has been deleted.The study was unblinded following 
DMC recommendation, necessitating 
this amendment to update the timing of the primary OS analysis and to simplify study procedures following unblinding.
3.1: Study Design and DurationPost-treatment follow-up instructions revised to remove 
contrast MRI.
BICR submission will stop with 
unblinding, clarification added.Following study unblinding, the collection of imaging data for analysis purposes is not relevant; BICR and post-treatment imaging 
data is no longer needed.
Summary: Study Schematic Figure 
3.1-1: Study Design SchematicSchematic figure updated to: safety only following unblinding
Clarification added below figure 
indicating that followingunblinding, subjects may continue on treatment.Aligned with changes concerning study unblinding.
Summary: Study Assessments
3.1.3: Follow-up PhasesFollow up procedures have been 
further clarified.
Instructions for assessments after 
treatment discontinuation for reasons other than disease progression have been removed.Aligned with simplified procedures following study unblinding; 
3.1.4: Overall Study DurationUpdates due to unblinding, including the timing of study 
closure, have been made.The study was unblinded following 
DMC recommendation; the OS primary analysis will include data through the date of study unblinding. Additional OS data are not required, 
so the study will clo se following all 
subjectsâ€™ treatment discontinuation 
and safety follow-up.
3.3.1: Inclusion CriteriaMale contraception requirements 
revised for Inclusion Criterion 3e. Updated per BMS standard for all studies with nivolumab.
3.5: Discontinuation of Subjects following any Treatment with 
Study DrugPost-treatment follow-up for 
progression and survival has been 
removed.Aligned with changes concerning 
study unblinding.
Protocol Amendment No.: 07
Date: 02-Sep-2021 121
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Summary of key changes of Protocol Amendment 06
Section Number & Title Description of Change Brief Rationale
3.6: Post Study Drug Follow-upPost-treatment follow-up for 
survival has been removed.Aligned with changes concerning study unblinding.
4.5.1: Nivolumab/Placebo Dosing Unblinding clarification added.Due to study unblinding, the provisions for dosing and dose 
modification no longer apply for the 
placebo treatment arm.
[IP_ADDRESS]: Dose Delay Criteria for 
Nivolumab/Placebo
[IP_ADDRESS]: Criteria to Resume Dosing 
for Nivolumab/PlaceboAdded SARS-CoV-[ADDRESS_259085] for COVID-19 protocol language.
[IP_ADDRESS]: Treatment Discontinuation Criteria for Nivolumab/PlaceboDecision by [CONTACT_215337].Aligned with changes concerning 
study unblinding.
4.6: Blinding/UnblindingStatement regarding unblinding has been added.The study was unblinded following DMC recommendation, necessitating 
this amendment to update the timing of the primary OS analysis and to simplify study procedures following unblinding.
Table 5.1-2: On-treatment 
Assessments
Table 5.1-3: Treatment Follow-up 
and Survival Follow-upFootnote â€˜aâ€™ added to chemistry panel row.
Footnote â€˜aâ€™ updated to clarify 
chemistry panel collection in relation to TMZ dosing.
 
 
notes 
clarified to include instructions following unblinding.
Footnote â€˜aâ€™ updated to add 
instructions following unblinding.
Footnote â€˜bâ€™ updated to clarify that 
survival follow-up visits do not 
occur following unblinding.Aligned with simplified procedures following study unblinding; 
subsequent response, survival,  
 are no 
longer needed.
5.3: Safety AssessmentsClarification for subjects on TMZ 
treatment following placebo 
discontinuation has been added.
Instruction to evaluate for cardiac 
or pulmonary toxicity has been 
added.Aligned with changes concerning study unblinding.
Updated per BMS standard for all 
studies with nivolumab.
Protocol Amendment No.: 07
Date: 02-Sep-2021 122
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Summary of key changes of Protocol Amendment 06
Section Number & Title Description of Change Brief Rationale
5.4: Efficacy Assessments
5.8.3: Results of Central Radiology 
AssessmentsClarification has been added to discontinue BICR submission, 
 
 following unblinding.Aligned with simplified procedures following study unblinding; 
subsequent response data  
are no 
longer needed.
6.1.1: Serious Adverse Event Collection and Reporting
6.2.1: Nonserious Adverse Event 
Collection and Reporting
6.4: PregnancyClarification has been added 
concerning SAEs and non-serious AEs related to SARS-CoV-2.
Clarification for collection of 
nonserious AEs for a minimum of [ADDRESS_259086] for 
COVID-19 protocol language.
Aligned with simplified procedures 
following study unblinding; continued AE collection is not needed for subjects discontinuing the placebo treatment arm. Subjects in the placebo treatment arm who 
discontinue TMZ treatment require 
[ADDRESS_259087] for all nivolumab studies. 
Protocol Amendment No.: 07
Date: 02-Sep-2021 123
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Summary of key changes of Protocol Amendment 06
Section Number & Title Description of Change Brief Rationale
Summary: Primary Endpoints
8.1: Sample Size Determination
[IP_ADDRESS]: Analyses of Primary 
Endpoint
8.5: Interim AnalysesStatement describing the impact of 
DMC unblinding decision has been added. 
Statistical description of the 
primary OS analysis has been updated.
PFS interim analysis updated per 
Administrative Letter 10.The study was unblinded following DMC recommendation; the OS primary analysis will include data through the date of study unblinding, and is no longer event driven.
The PFS interim analysis was 
removed.
Summary: Secondary Endpoints
[IP_ADDRESS]: Analyses of Secondary 
EndpointsClarification for the timing of secondary endpoint analysis added.Aligned with updated timing for the OS primary analysis. 
8.6: End of Study Analyses at Study ClosureSection added to describe what analyses will occur at study closure 
once all post unblinding data have been collected.Subjects may remain on study 
treatment post unblinding and will be 
followed through the safety follow-up phase. Limited reporting will be completed as described in the analysis plan.
Overall Rationale for Revised Protocol 05, 08-Nov-2018
Per Revised Protocol 05, progressi on free s urvival (PFS) has been changed from a secondary to a 
primary ob jective of the study. In s upport of this change, blinded independent central review 
(BICR) has been added and may occur at any time during the stud y. Overall survival (OS) rate at 
[ADDRESS_259088] also been incorporated.
Summary of key changes of Revised Protocol 05
Section Number & Title Description of Change Brief Rationale
â€¢Synopsis, Objectives, Research 
Hypothesis, and Study Schema
â€¢Sections 1.3.1 and 1.3.2  Primary and Secondary ObjectivesChange of PFS to a primary rather than a secondary objective.
Addition of OS rate at 12 and 24 
month as a secondary objective.PFS has been changed to a primary objective of the study and is 
supported by [CONTACT_215338]. 
PFS as surrogate survival marker enables an earlier assessment of treatment effects. 
Survival rates at 12 and 24 months 
are widely used endpoints in 
Protocol Amendment No.: 07
Date: 02-Sep-2021 124
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Summary of key changes of Revised Protocol 05
Section Number & Title Description of Change Brief Rationale
â€¢Section 3.1 Study Design and 
Duration and Figure 3.1-1  
Study Design Schematic neuro -oncology to better describe 
long-term survival or a â€œplateauâ€.
â€¢Synopsis Objectives
â€¢Section 1.3.2 and 1.3.3 
Secondary  
Objectives PFS based on investigator 
assessment by [CONTACT_215339] a secondary objective.As a secondary endpoint, PFS will 
also be estimated by [CONTACT_215340]. 
â€¢Synopsis, Study Assessments
â€¢5.4 Efficacy AssessmentsLanguage added to specify that study images will be submitted to a central imaging vendor for 
blinded independent central 
review (BICR) at any time during the study.The addition of BICR supports the change of PFS to a primary objective of the study. BICR performed by 
[CONTACT_215341] a central 
facility provides the most objective evaluation of the PFS endpoint. 
â€¢Synopsis, Statistical 
Considerations
â€¢Section 8: Statistical 
ConsiderationsThe statistical section has been 
revised to support changes in the 
study objectives. Of note, the study will now include 1 formal interim analysis for PFS and 1 formal interim analyses for OSfor superiority.Aligned with changes in study 
objectives.
â€¢Section 3.1.[ADDRESS_259089] changes in the study objectives and interim analyses. Aligned with changes in study objectives and updated statistical considerations.
â€¢Section 3.3.1, Inclusion Criteria, 4. Physical and 
Laboratory Test Findings e) Updated to:
Serum creatinine â‰¤1.[ADDRESS_259090] 
unless ( changed from or ) 
creatinine clearance (CrCl) â‰¥50 
mL/min) (measured or calculated 
[added ] using the Cockcroft-
Gault formula)Aligned with BMS standard for studies of nivolumab in subjects with 
glioblastoma.
â€¢Section 3.3.2 Exclusion Criteria 
2) Medical History 
â€¢Section 3.4.1 Prohibited and/or Restricted Treatments Treatment with any live/attenuated vaccine (eg varicella, zoster, yellow fever, rotavirus, oral polio and measles, 
mumps, rubella (MMR)) has been 
added as an exclusion criterion and is prohibited during treatment and until [ADDRESS_259091] for all studies with nivolumab.
Protocol Amendment No.: 07
Date: 02-Sep-2021 125
Approved 8.0 v

Clinical Protocol CA209548
BMS-936558 nivolumab
Summary of key changes of Revised Protocol 05
Section Number & Title Description of Change Brief Rationale
â€¢Section [IP_ADDRESS] Imaging 
Restriction and PrecautionsStandard language for imaging added to this sectionUpdates per BMS standard.
â€¢Section [IP_ADDRESS] Treatment Discontinuation Criteria for 
Nivolumab/PlaceboUpdated to:
Grade 3 drug-related uveitis, 
pneumonitis, bronchospasm, neurologic toxicity , [added], 
myocarditis [added], 
hypersensitivity reaction, or infusion reaction of any duration requires discontinuationUpdated to BMS standard for all studies with nivolumab.
â€¢Section 5.6.1. Tumors Samples Subsections revised to align with 
standard BMS practice.Update per BMS technology standard.
â€¢Appendix 1: Hepatic Adverse Event Management AlgorithmDeletion of footnote stating I-O therapy may be delayed rather 
than discontinued if AST/ALT â‰¤ [ADDRESS_259092] or T.bili â‰¤ [ADDRESS_259093] o n protocol 
content.
Protocol Amendment No.: 07
Date: 02-Sep-2021 126
Approved 8.0 v
